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WHO World Health Organization
1. Preamble
Guidelines summarize and evaluate all available evidence, at the
time of the writing process, on a particular issue with the aim of
assisting physicians in selecting the best management strategies
for an individual patient, with a given condition, taking into
account the impact on outcome, as well as the risk–benefit ratio
of particular diagnostic or therapeutic means. Guidelines are no
substitutes but are complements for textbooks and cover the
European Society of Cardiology (ESC) Core Curriculum topics.
Guidelines and recommendations should help the physicians to
make decisions in their daily practice. However, the final decisions
concerning an individual patient must be made by the responsible
physician(s).
A great number of Guidelines have been issued in recent years
by the ESC as well as by other societies and organizations. Because
of the impact on clinical practice, quality criteria for the develop-
ment of guidelines have been established in order to make all
decisions transparent to the user. The recommendations for for-
mulating and issuing ESC Guidelines can be found on the ESC
website (http://www.escardio.org/guidelines-surveys/esc-guidelines/
about/Pages/rules-writing.aspx). ESC Guidelines represent the official
position of the ESC on a given topic and are regularly updated.
Members of this Task Force were selected by the ESC to rep-
resent professionals involved with the medical care of patients
with this pathology. Selected experts in the field undertook a com-
prehensive review of the published evidence for diagnosis, manage-
ment, and/or prevention of a given condition according to ESC
Committee for Practice Guidelines (CPG) policy. A critical
evaluation of diagnostic and therapeutic procedures was per-
formed including assessment of the risk–benefit ratio. Estimates
of expected health outcomes for larger populations were included,
where data exist. The level of evidence and the strength of
recommendation of particular treatment options were weighed
and graded according to pre-defined scales, as outlined in
Tables 1 and 2.
The experts of the writing and reviewing panels filled in declara-
tions of interest forms which might be perceived as real or poten-
tial sources of conflicts of interest. These forms were compiled
into one file and can be found on the ESC Web Site (http://
www.escardio.org/guidelines). Any changes in declarations of inter-
est that arise during the writing period must be notified to the ESC
and updated. The Task Force received its entire financial support
from the ESC without any involvement from healthcare industry.
The ESC CPG supervises and coordinates the preparation of
new Guidelines produced by Task Forces, expert groups, or con-
sensus panels. The Committee is also responsible for the endorse-
ment process of these Guidelines. The ESC Guidelines undergo
extensive review by the CPG and external experts. After appropri-
ate revisions it is approved by all the experts involved in the Task
Force. The finalized document is approved by the CPG for publi-
cation in the European Heart Journal.
The task of developing Guidelines covers not only the inte-
gration of the most recent research, but also the creation of edu-
cational tools and implementation programmes for the
recommendations. To implement the guidelines, condensed
pocket guidelines versions, summary slides, booklets with essential
messages, and an electronic version for digital applications (smart-
phones, etc.) are produced. These versions are abridged and, thus,
if needed, one should always refer to the full text version which is
freely available on the ESC website.
The National Societies of the ESC are encouraged to endorse,
translate, and implement the ESC Guidelines. Implementation
Table 1 Classes of recommendation
Classes of 
recommendations
Definition Suggested wording to use
Class I Evidence and/or general agreement 
that a given treatment or procedure 
is beneficial, useful, effective. 
Is recommended/is 
indicated
Class II Conflicting evidence and/or a 
divergence of opinion about the 
usefulness/efficacy of the given 
treatment or procedure. 
    Class IIa Weight of evidence/opinion is in 
favour of usefulness/efficacy. 
Should be considered
    Class IIb Usefulness/efficacy is less well 
established by evidence/opinion. 
May be considered
Class III Evidence or general agreement that 
the given treatment or procedure 
is not useful/effective, and in some 
cases may be harmful. 
Is not recommended
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programmes are needed because it has been shown that the
outcome of disease may be favourably influenced by the thorough
application of clinical recommendations.
Surveys and registries are needed to verify that real-life daily
practice is in keeping with what is recommended in the guidelines,
thus completing the loop between clinical research, writing of
guidelines, and implementing them into clinical practice.
The guidelines do not, however, override the individual respon-
sibility of health professionals to make appropriate decisions in the
circumstances of the individual patients, in consultation with that
patient, and, where appropriate and necessary, the patient’s guar-
dian or carer. It is also the health professional’s responsibility to
verify the rules and regulations applicable to drugs and devices at
the time of prescription.
2. General considerations
2.1 Introduction
At present, 0.2–4% of all pregnancies in western industrialized
countries are complicated by cardiovascular diseases (CVD),1
and the number of the patients who develop cardiac problems
during pregnancy is increasing. Nevertheless, the number of such
patients presenting to the individual physician is small. However,
knowledge of the risks associated with CVD during pregnancy
and their management are of pivotal importance for advising
patients before pregnancy. Therefore, guidelines on disease man-
agement in pregnancy are of great relevance. Such guidelines
have to give special consideration to the fact that all measures
concern not only the mother, but the fetus as well. Therefore,
the optimum treatment of both must be targeted. A therapy
favourable for the mother can be associated with an impairment
of the child, and in extreme cases treatment measures which
protect the survival of the mother can cause the death of the
fetus. On the other hand, therapies to protect the child may
lead to a suboptimal outcome for the mother. Because prospective
or randomized studies are lacking, with a few exceptions, rec-
ommendations in this guideline mostly correspond to the evidence
level C.
Some general conclusions have arisen from these guidelines:
counselling and management of women of childbearing age with
suspected cardiac disease should start before pregnancy occurs;
they should be managed by interdisciplinary teams; high risk
patients should be treated in specialized centres; and diagnostic
procedures and interventions should be performed by specialists
with great expertise in the individual techniques and experience
in treating pregnant patients. Registries and prospective studies
are urgently needed to improve the state of knowledge.
2.2 Methods
The Guidelines are based on a systematic search of the literature
of the last 20 years in the National Institutes of Health database
(PubMed). The publications and recommendations of the Euro-
pean and American cardiological societies are also considered:
American Heart Association/American College of Cardiology
(AHA/ACC),2 the ESC in 2003,3 the Working Group Valvular
Heart Disease of the ESC,4 the guidelines of the German Society
of Cardiology (German Society of Cardiology),5,6 and the ESC
Task Force on the Management of Valvular Heart Disease 2007.7
2.3 Epidemiology
The spectrum of CVD in pregnancy is changing and differs
between countries. In the western world, the risk of CVD in preg-
nancy has increased due to increasing age at first pregnancy and
increasing prevalence of cardiovascular risk factors—diabetes,
hypertension, and obesity. Also the treatment of congenital heart
disease has improved, resulting in an increased number of
women with heart disease reaching childbearing age.8 In western
countries maternal heart disease is now the major cause of
maternal death during pregnancy.9
Hypertensive disorders are the most frequent cardiovascular
events during pregnancy, occurring in 6–8% of all pregnancies.10
In the western world, congenital heart disease is the most frequent
cardiovascular disease present during pregnancy (75–82%), with
shunt lesions predominating (20–65%).11,12 Congenital heart
disease represents just 9–19% outside Europe and North
America. Rheumatic valvular disease dominates in non-western
countries, comprising 56–89% of all cardiovascular diseases in
pregnancy.11,12
Cardiomyopathies are rare, but represent severe causes of car-
diovascular complications in pregnancy. Peripartum cardiomyopa-
thy (PPCM) is the most common cause of severe complications.13
2.4 Haemodynamic, haemostatic, and
metabolic alterations during pregnancy
Pregnancy induces changes in the cardiovascular system to meet
the increased metabolic demands of the mother and fetus. They
include increases in blood volume and cardiac output (CO), and
reductions in systemic vascular resistance and blood pressure (BP).
Plasma volume reaches a maximum of 40% above baseline at 24
weeks gestation. A 30–50% increase in CO occurs in normal preg-
nancy. In early pregnancy increased CO is primarily related to the
rise in stroke volume; however, in late pregnancy, heart rate is the
major factor. Heart rate starts to rise at 20 weeks and increases
until 32 weeks. It remains high 2–5 days after delivery. Systemic
BP (SBP) typically falls early in gestation and diastolic BP (DBP)
is usually 10 mmHg below baseline in the second trimester. This
decrease in BP is caused by active vasodilatation, achieved
Table 2 Levels of evidence
Level of 
Evidence A 





Data derived from a single randomized 
clinical trial 
or large non-randomized studies. 
Level of 
Evidence C 
Consensus of opinion of the experts and/
or small studies, retrospective studies, 
registries.
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through the action of local mediators such as prostacyclin and
nitric oxide. In the third trimester, the DBP gradually increases
and may normalize to non-pregnant values by term.
The heart can increase its size by up to 30%, which is partially
due to dilatation. Data regarding systolic and diastolic function in
pregnancy are scarce. Systolic function increases first but may
decrease in the last trimester. Reports on diastolic function are
conflicting.
Pregnancy induces a series of haemostatic changes, with an
increase in concentration of coagulation factors, fibrinogen, and
platelet adhesiveness, as well as diminished fibrinolysis, which lead
to hypercoagulability and an increased risk of thrombo-embolic
events. In addition, obstruction to venous return by the enlarging
uterus causes stasis and a further rise in risk of thrombo-embolism.
Maternal glucose homeostasis may change and cholesterol levels
increase in adaptation to fetal–maternal needs.
Physiological changes that occur during pregnancy can affect
absorption, excretion, and bioavailability of all drugs.14 The
increased intravascular blood volume partly explains the higher
dosages of drugs required to achieve therapeutic plasma concen-
trations, and the dose adaptations needed during treatment. More-
over, the raised renal perfusion and the higher hepatic metabolism
increase drug clearance. The altered pharmacokinetics of drugs
vary in magnitude during different stages of pregnancy, making
careful monitoring of the patient and dose adjustments necessary.
Uterine contractions, positioning (left lateral vs. supine), pain,
anxiety, exertion, bleeding, and uterine involution cause significant
haemodynamic changes during labour and post-partum. Anaesthe-
sia, analgesia, haemorrhage, and infection may induce additional
cardiovascular stress. SBP and DBP increase 15–25% and 10–
15%, respectively, during uterine contractions. Such increases are
associated with a rise in pressure in the amniotic fluid, and in the
intrathoracic venous, cerebrospinal, and extradural fluids. CO
increases by 15% in early labour, by 25% during stage 1, and by
50% during expulsive efforts.15 It reaches an increase of 80%
early post-partum due to autotransfusion associated with uterine
involution and resorption of leg oedema.
In conclusion, the physiological adaptations to pregnancy influ-
ence the evaluation and interpretation of cardiac function and clini-
cal status.
2.5 Genetic testing and counselling
An important aspect concerning the care of young women with
CVD is the consultation about the risk of inheritance of cardiac
defects for their descendants. The risk is raised significantly in com-
parison with parents without CVD where the risk is 1%. In
addition, there are large differences between each of the heredi-
tary heart disease conditions, and the risk for descendants is
dependent on whether only the mother, only the father, or both
parents suffer from hereditary cardiac defects.16 In general, the
risk is higher when the mother is affected rather than the
father.16 The recurrence risk varies between 3% and 50% depend-
ing on the type of maternal heart disease.
Children of parents with a cardiovascular condition inherited in
an autosomal dominant manner (e.g. Marfan syndrome, hyper-
trophic cardiomyopathy, or long QT syndrome) have an inheri-
tance risk of 50%, regardless of gender of the affected parent.
The final phenotype will also be determined by incomplete pene-
trance and pleiotropic effects, and may vary significantly. For
defects that are inherited in a polygenic manner, recurrence risk
is less clearly defined. Autosomal recessive and X-chromosomal
recessive inheritance are rare.
Genetic testing may be useful:
† in cardiomyopathies and channelopathies, such as long QT
syndromes17
† when other family members are affected
† when the patient has dysmorphic features, developmental delay/
mental retardation, or when other non-cardiac congenital
abnormalities are present, in syndromes such as in Marfan,
22q11 deletion, Williams–Beuren, Alagille, Noonan, and
Holt–Oram syndrome.
For a steadily increasing number of genetic defects, genetic screen-
ing by chorionic villous biopsy can be offered in the 12th week of
pregnancy. All women with congenital heart disease should be
offered fetal echocardiography in the 19th to 22nd week of preg-
nancy. Measurement of nuchal fold thickness in the 12th to 13th
week of pregnancy is an early screening test for women over 35
years of age. The sensitivity for the presence of a significant
heart defect is 40%, while the specificity of the method is 99%.
The incidence of congenital heart disease with normal nuchal
fold thickness is 1/1000.18
The inheritance pattern differs among the diseases, and there-
fore genetic counselling by a geneticist is highly recommended
for patients and their family members.17 Genetic testing after
careful counselling has the rationale of identifying at-risk asympto-
matic or disease-free relatives and to guide clinical surveillance for
disease onset, thereby enhancing preventive and treatment inter-
ventions. It is advocated in patients with known genetic disorders
and is more advisable if treatment options are available.17
2.6 Cardiovascular diagnosis
in pregnancy
The following procedures are of relevance for the diagnosis and
management of CVD in pregnancy.
History and clinical investigation
Many disorders can be identified by taking a careful personal and
family history, particularly cardiomyopathies, the Marfan syn-
drome, congenital heart disease, juvenile sudden death, long
QT syndrome, and catecholaminergic ventricular tachycardia
(VT) or Brugada syndrome. It is important to ask specifically
about possible sudden deaths in the family. The assessment of
dyspnoea is important for diagnosis and prognosis of valve
lesions and for heart failure. A thorough physical examination
considering the physiological changes that occur during preg-
nancy (Section 2.4) is mandatory, including auscultation for
new murmurs, changes in murmurs, and looking for signs of
heart failure. When dyspnoea occurs during pregnancy or
when a new pathological murmer is heard, echocardiography is
indicated. It is crucial to measure the BP, in left lateral recum-
bency (see Section 9) using a standardized method, and to
look for proteinuria, especially with a history or family history
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of hypertension or pre-eclampsia. Oximetry should be per-
formed in patients with congenital heart disease.
Electrocardiography
The great majority of pregnant patients have a normal electrocar-
diogram (ECG). The heart is rotated towards the left and on the
surface ECG there is a 15–20 left axis deviation. Common findings
include transient ST segment and T wave changes, the presence of
a Q wave and inverted T waves in lead III, an attenuated Q wave in
lead AVF, and inverted T waves in leads V1, V2, and, occasionally,
V3. ECG changes can be related to a gradual change in the position
of the heart and may mimic left ventricular (LV) hypertrophy and
other structural heart diseases.
Holter monitoring should be performed in patients with known
previous paroxysmal or persistent documented arrhythmia [VT,
atrial fibrillation (AF), or atrial flutter] or those reporting symp-
toms of palpitations.
Echocardiography
Because echocardiography does not involve exposure to radiation,
is easy to perform, and can be repeated as often as needed, it has
become an important tool during pregnancy and is the preferred
screening method to assess cardiac function.
Transoesophageal echocardiography
Multiplane transducers have made transoesophageal echocardio-
graphy a very useful echocardiographic method in the assessment
of adults with, for example, complex congenital heart disease.
Transoesophageal echocardiography, although rarely required, is
relatively safe during pregnancy. The presence of stomach con-
tents, risk of vomiting and aspiration, and sudden increases in
intra-abdominal pressure should be taken into account, and fetal
monitoring performed if sedation is used.
Exercise testing
Exercise testing is useful to assess objectively the functional
capacity, chronotropic and BP response, as well as
exercise-induced arrhythmias. It has become an integral part of
the follow-up of grown up congenital heart disease patients as
well as patients with asymptomatic valvular heart disease.19,20 It
should be performed in patients with known heart disease, prefer-
ably prior to pregnancy to assist in risk assessment.
This Committee recommends performing submaximal exercise
tests to reach 80% of predicted maximal heart rate in asympto-
matic pregnant patients with suspected CVD. There is no evidence
that it increases the risk of spontaneous abortion.21 Semi-
recumbent cycle ergometry appears to be the most comfortable
modality, but treadmill walking or upright cycle ergometry may
also be used. Dobutamine stress should be avoided. If respiratory
gas analysis is used, the limit is a respiratory exchange ratio of 1.0.
Stress echocardiography using bicycle ergometry may add to the
diagnostic specificity in detecting the presence and extent of
ischaemia in high risk patients with possible coronary artery
disease. This can also be useful prior to conception to assess myo-
cardial reserve in patients with prior PPCM and recovered LV func-
tion [left ventricular ejection fraction (LVEF)], and also in patients
with other cardiomyopathies, with valvular or congenital heart
disease with borderline or mildly reduced LVEF. Nuclear scintigra-
phy should be avoided during pregnancy because of radiation
exposure.
Radiation exposure
The effects of radiation on the fetus depend on the radiation dose
and the gestational age at which exposure occurs. If possible, pro-
cedures should be delayed until at least the completion of the
period of major organogenesis (.12 weeks after menses). There
is no evidence of an increased fetal risk of congenital malformations,
intellectual disability, growth restriction, or pregnancy loss at doses
of radiation to the pregnant woman of ,50 mGy22,23 (www.bt.cdc.
gov/radiation/prenatalphysician.asp; accessed 31 October 2007).
There may be a small increase in risk (1:2000 vs. 1:3000) of childhood
cancer. The threshold at which an increased risk of congenital mal-
formations occurs has not been definitely determined. Some evi-
dence suggests that risk of malformations is increased at doses
.100 mGy, whereas the risk between 50 and 100 mGy is less
clear. During the first 14 days after fertilization, intact survival
without fetal abnormality or death are the most likely outcomes of
radiation exposure .50 mGy. After the first 14 days, radiation
exposure.50 mGy may be associated with an increased risk of con-
genital malformations, growth restriction, and intellectual disability.
Most medical procedures do not expose the fetus to such high
levels of radiation (Table 3). For the majority of diagnostic medical
procedures, involving doses to the fetus of up to 1 mGy, the
associated risks of childhood cancer are very low. (Documents
of the Health Protection Agency. Radiation, Chemical and Environ-
mental Hazards March 2009. RSE-9 Protection of pregnant patients
during diagnostic medical exposures to ionising radiation. Advice
from the Health Protection Agency, The Royal College of Radiol-
ogists, and the College of Radiographers.)
Table 3 Estimated fetal and maternal effective doses







<0.01 mGy <0.01 mSv 0.1 mGy 0.1 mSv
CT chest 0.3 mGy 0.3 mSv 7 mGy 7 mSv
Coronary 
angiographya




3 mGy 3 mSv 15 mGy 15 mSv
aExposure depends on the number of projections or views.
CT ¼ computed tomography; PA ¼ postero-anterior; PCI ¼ percutaneous
coronary intervention.
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As a general rule, according to the principle ‘as low as reason-
ably achievable’ (ALARA), all radiation doses due to medical
exposures must be kept as low as reasonably achievable.24
Chest radiograph
The fetal dose from a chest radiograph is ,0.01 mGy.25 Neverthe-
less, a chest radiograph should only be obtained if other methods
fail to clarify the cause of dyspnoea, cough, or other symptoms.23
If the required diagnostic information can be obtained with an
imaging modality that does not use ionizing radiation, it should
be used as a first-line test. If a study that uses ionizing radiation
has to be performed, the radiation dose to the fetus should be
kept as low as possible (preferably ,50 mGy). The risks and
benefits of performing or not performing the examination should
be communicated. Documentation of the radiation dose to the
mother in the medical records, particularly if the fetus is in the
field of view, is highly recommended.26,27
Magnetic resonance imaging and computed tomography
Magnetic resonance imaging (MRI) may be useful in diagnosing
complex heart disease or pathology of the aorta.28 It should only
be performed if other diagnostic measures, including transthoracic
and transoesophageal echocardiography, are not sufficient for
complete diagnosis. Limited data during organogenesis are avail-
able, but MRI is probably safe, especially after the first trimester.29
Gadolinium can be assumed to cross the fetal blood–placental
barrier, but data are limited. The long-term risks of exposure of
the developing fetus to free gadolinium ions30 are not known,
and therefore gadolinium should be avoided.
Computed tomography (CT)31 is usually not necessary to diag-
nose CVD during pregnancy and, because of the radiation dose
involved, is therefore not recommended. One exception is that
it may be required for the accurate diagnosis or definite exclusion
of pulmonary embolism. For this indication it is recommended if
other diagnostic tools are not sufficient (see Section 10). Low radi-
ation CT 1–3 mSv can be used in these situations.
Cardiac catheterization
During coronary angiography the mean radiation exposure to the
unshielded abdomen is 1.5 mGy, and ,20% of this reaches the
fetus because of tissue attenuation. Shielding the gravid uterus
from direct radiation and especially shortening fluoroscopic time
will minimize radiation exposure. The radial approach is preferable
and should be undertaken by an experienced operator. Most elec-
trophysiological studies aiming for ablation should only be per-
formed if arrhythmias are intractable to medical treatment and
cause haemodynamic compromise. If undertaken, electroanatomi-
cal mapping systems should be used to reduce the radiation
dose.32
General recommendations for diagnostic and therapeutic man-
agement during pregnancy are listed in Table 9.
2.7 Fetal assessment
First trimester ultrasound allows accurate measurement of gesta-
tional age and early detection of multiple pregnancy and of malfor-
mations. Diagnosis of congenital cardiac malformations can be
made as early as 13 weeks, and, in families with heart disease,
this timing is appropriate to start screening for congential heart
disease. A review of the accuracy of first-trimester ultrasounds
for detecting major congenital heart disease showed a sensitivity
and specificity of 85% [95% confidence interval (CI) 78–90%]
and 99% (95% CI 98–100%), respectively. Early examination in
pregnancy allows parents to consider all options, including termin-
ation of pregnancy, if there are major malformations.33
The optimum time for screening of normal pregnancies for con-
genital heart diseases34 is 18–22 weeks of gestation when visual-
ization of the heart and outflow tracts is optimal. It becomes
more difficult after 30 weeks since the fetus is more crowded
within the amniotic cavity. Second-trimester screening (18–22
weeks) for detection of fetal anomalies should be performed by
experienced specialists, particularly in pregnancies with risk
factors for congenital heart anomalies.35
Cardiac anatomy and function, arterial and venous flow, and
rhythm should be evaluated. When a fetal cardiac anomaly is sus-
pected, it is mandatory to obtain the following.
(1) A full fetal echocardiography to evaluate cardiac structure and
function, arterial and venous flow, and rhythm.
(2) Detailed scanning of the fetal anatomy to look for associated
anomalies (particularly the digits and bones).
(3) Family history to search for familial syndromes.
(4) Maternal medical history to identify chronic medical disorders,
viral illnesses, or teratogenic medications.
(5) Fetal karyotype (with screening for deletion in 22q11.2 when
conotruncal anomalies are present).
(6) Referral to a maternal–fetal medicine specialist, paediatric car-
diologist, geneticist, and/or neonatologist to discuss prognosis,
obstetric, and neonatal management, and options.
(7) Delivery at an institution that can provide neonatal cardiac
care, if needed.
Doppler velocimetry (uterine, umbilical, fetal renal, and cerebral
arteries, and descending aorta) provides a non-invasive measure
of the fetoplacental haemodynamic state. Abnormality of the
Doppler index in the umbilical artery correlates to fetoplacental
vascular maldevelopment, fetal hypoxia, acidosis, and adverse peri-
natal outcome. The most ominous pre-terminal findings of the
umbilical artery Doppler waveform are absent end-diastolic vel-
ocity and reversed end-diastolic velocity. Reversed end-diastolic
velocity beyond 28 weeks should prompt immediate delivery by
caesarean delivery. Absent end-diastolic velocity should prompt
immediate consideration of delivery beyond 32 completed
weeks.36
Fetal biophysical profile testing is indicated in pregnancies at risk
of fetal compromise. Testing should be performed one or more
times per week, depending upon the clinical situation. Four echo-
graphic biophysical variables (fetal movement, tone, breathing, and
amniotic fluid volume) and results of non-stress testing are used
for scoring. Their presence implies absence of significant
central nervous system hypoxaemia/acidaemia. A compromised
fetus exhibits loss of accelerations of the fetal heart rate, decreased
body movement and breathing, hypotonia, and, less acutely,
decreased amniotic fluid volume. From 70% to 90% of late fetal
deaths display evidence of chronic and/or acute compromise.
Sonographic detection of signs of fetal compromise can allow
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appropriate intervention that ideally will prevent adverse fetal
sequelae.37,38
2.8 Interventions in the mother during
pregnancy
2.8.1 Percutaneous therapy
The same restrictions which apply for diagnostic coronary angio-
graphy (see Section 2.6) are relevant. If an intervention is absol-
utely necessary, the best time to intervene is considered to be
after the fourth month in the second trimester. By this time orga-
nogenesis is complete, the fetal thyroid is still inactive, and the
volume of the uterus is still small, so there is a greater distance
between the fetus and the chest than in later months. Fluoroscopy
and cineangiography times should be as brief as possible and the
gravid uterus should be shielded from direct radiation. Heparin
has to be given at 40–70 U/kg, targeting an activated clotting
time of at least 200 s, but not exceeding 300 s.
2.8.2 Cardiac surgery with cardiopulmonary bypass
Maternal mortality during cardiopulmonary bypass is now similar
to that in non-pregnant women who undergo comparable
cardiac procedures.1 However, there is significant morbidity
including late neurological impairment in 3–6% of children, and
fetal mortality remains high.39 For this reason cardiac surgery is
recommended only when medical therapy or interventional pro-
cedures fail and the mother’s life is threatened. The best period
for surgery is between the 13th and 28th week.40,41 Surgery
during the first trimester carries a higher risk of fetal malfor-
mations, and during the third trimester there is a higher inci-
dence of pre-term delivery and maternal complications. We
know from previous studies that gestational age has a large
impact on neonatal outcome.42 Recent improvement in neonatal
care has further improved survival of premature infants. At 26
weeks, survival is generally 80%, with 20% having serious
neurological impairment. For this reason, caesarean delivery
may be considered before cardiopulmonary bypass if gestational
age is .26 weeks.43 Whether or not delivery is advantageous
for the baby at this gestational age depends on several factors:
gender, estimated weight, prior administration of corticosteroids
before delivery, and the outcome statistics of the neonatal unit
concerned. When gestational age is 28 weeks or more, delivery
before surgery should be considered. Before surgery a full
course (at least 24 h) of corticosteroids should be administered
to the mother, whenever possible. During cardiopulmonary
bypass, fetal heart rate and uterine tone should be monitored
in addition to standard patient monitoring. Pump flow .2.5 L/
min/m2 and perfusion pressure .70 mmHg are mandatory to
maintain adequate utero-placental blood flow; pulsatile flow,
although controversial, seems more effective for preserving uter-
oplacental blood flow. Maternal haematocrit .28% is rec-
ommended to optimize the oxygen delivery. Normothermic
perfusion, when feasible, is advocated, and state of the art pH
management is preferred to avoid hypocapnia responsible for
uteroplacental vasoconstriction and fetal hypoxia. Cardiopulmon-
ary bypass time should be minimized.44
2.9 Timing and mode of delivery: risk for
mother and child
High risk delivery
Induction, management of labour, delivery, and post-partum sur-
veillance require specific expertise and collaborative management
by skilled cardiologists, obstetricians, and anaesthesiologists, in
experienced maternal–fetal medicine units.45,46
Timing of delivery
Spontaneous onset of labour is appropriate for women with
normal cardiac function and is preferable to induced labour for
the majority of women with heart disease. Timing is individualized,
according to the gravida’s cardiac status, Bishop score (a score
based upon the station of the presenting part and four character-
istics of the cervix: dilatation, effacement, consistency, and pos-
ition), fetal well-being, and lung maturity. Due to a lack of
prospective data and the influence of individual patient character-
istics, standard guidelines do not exist, and management should
therefore be individualized. In women with mild unrepaired conge-
nital heart disease and in those who have undergone successful
cardiac surgical repair with minimal residua, the management of
labour and delivery is the same as for normal pregnant women.
Labour induction
Oxytocin and artificial rupture of the membranes are indicated
when the Bishop score is favourable. A long induction time
should be avoided if the cervix is unfavourable. While there is
no absolute contraindication to misoprostol or dinoprostone,
there is a theoretical risk of coronary vasospasm and a low risk
of arrhythmias. Dinoprostone also has more profound effects on
BP than prostaglandin E1 and is therefore contraindicated in
active CVD. Mechanical methods such as a Foley catheter would
be preferable to pharmacological agents, particularly in the
patient with cyanosis where a drop in systemic vascular resistance
and/or BP would be detrimental.47
Vaginal or caesarean delivery
The preferred mode of delivery is vaginal, with an individualized
delivery plan which informs the team of timing of delivery (spon-
taneous/induced), method of induction, analgesia/regional anaes-
thesia, and level of monitoring required. In high risk lesions,
delivery should take place in a tertiary centre with specialist
multidisciplinary team care. Vaginal delivery is associated with
less blood loss and infection risk compared with caesarean deliv-
ery, which also increases the risk of venous thrombosis and
thrombo-embolism.48 In general, caesarean delivery is reserved
for obstetric indications. There is no consensus regarding absolute
contraindications to vaginal delivery as this is very much dependent
on maternal status at the time of delivery and the anticipated
cardiopulmonary tolerance of the patient. Caesarean delivery
should be considered for the patient on oral anticoagulants
(OACs) in pre-term labour, patients with Marfan syndrome and
an aortic diameter .45 mm, patients with acute or chronic
aortic dissection, and those in acute intractable heart failure.
Cesarean delivery may be considered in Marfan patients with an
aortic diameter 40–45 mm.7,49,50 (see also Section 4.3).
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In some centres, caesarean delivery is advocated for women with
severe aortic stenosis (AS) and in patients with severe forms of pul-
monary hypertension (including Eisenmenger syndrome), or acute
heart failure.7,46 (see specific sections). Caesarean delivery may be
considered in patients with mechanical heart valve prostheses to
prevent problems with planned vaginal delivery. In such patients, a
prolonged switch to heparin/low molecular weight heparin
(LMWH) may indeed be required for a long time before vaginal
birth, particularly, when the obstetrical situation is unfavourable.
This would increase the maternal risk (see also Sections 5.5 and 5.6).
Haemodynamic monitoring
Systemic arterial pressure and maternal heart rate are monitored,
because lumbar epidural anaesthesia may cause hypotension. Pulse
oximetry and continuous ECG monitoring are utilized as required.
A Swan–Ganz catheter for haemodynamic monitoring is rarely if
ever indicated due to the risk of arrhythmia provocation, bleeding,
and thrombo-embolic complications on removal.51
Anaesthesia/analgesia
Lumbar epidural analgesia is often recommendable because it
reduces pain-related elevations of sympathetic activity, reduces
the urge to push, and provides anaesthesia for surgery. Continuous
lumbar epidural analgesia with local anaesthetics or opiates, or
continuous opioid spinal anaesthesia can be safely administered.
Regional anaesthesia can, however, cause systemic hypotension
and must be used with caution in patients with obstructive valve
lesions. Intravenous (i.v.) perfusion must be monitored carefully.52
Labour
Once in labour, the woman should be placed in a lateral decubitus
position to attenuate the haemodynamic impact of uterine con-
tractions.53 The uterine contractions should descend the fetal
head to the perineum, without maternal pushing, to avoid the
unwanted effects of the Valsalva manoeuvre.54,55
Delivery may be assisted by low forceps or vacuum extraction.
Routine antibiotic prophylaxis is not recommended. Continuous
electronic fetal heart rate monitoring is recommended.
Delivery in anticoagulated women with prosthetic valves
OACs should be switched to LMWH or unfractionated heparin
(UFH) from the 36th week. Women treated with LMWH should
be switched to i.v. UFH, at least 36 h before the induction of
labour or caesarean delivery. UFH should be discontinued 4–6 h
before planned delivery, and restarted 4–6 h after delivery if
there are no bleeding complications (see also Section 5.5).
Urgent delivery in a patient with a mechanical valve taking thera-
peutic anticoagulation may be necessary, and there is a high risk
of severe maternal haemorrhage. If emergent delivery is necessary
while the patient is still on UFH or LMWH, protamine should be
considered. Protamine will only partially reverse the anticoagulant
effect of LMWH. In the event of urgent delivery in a patient on
therapeutic OACs, caesarean delivery is preferred to reduce the
risk of intracranial haemorrhage in the fully anticoagulated fetus.
If emergent delivery is necessary, fresh frozen plasma should be
given prior to caesarean delivery to achieve a target international
normalized ratio (INR) of ≤2.4 Oral vitamin K (0.5–1 mg) may
also be given, but it takes 4–6 h to influence the INR. If the
mother was on OACs at the time of delivery, the anticoagulated
newborn may be given fresh frozen plasma and should receive
vitamin K. The fetus may remain anticoagulated for 8–10 days
after discontinuation of maternal OACs.
Ventricular arrhythmias during pregnancy and labour
Arrhythmias are the most common cardiac complication during preg-
nancy in women with and without structural heart disease.12,56,57
They may manifest for the first time during pregnancy, or pregnancy
may exacerbate pre-existing arrhythmias.58–60 The 2006 ACC/AHA/
ESC guidelines for management of patients with ventricular arrhyth-
mias and the prevention of sudden cardiac death recommend that
pregnant women with prolonged QT syndrome who have had symp-
toms benefit from continued b-blocker therapy throughout preg-
nancy, during delivery, and post-partum unless there are definite
contraindications. Use of b-blockers during labour does not
prevent uterine contractions and vaginal delivery.61
Post-partum care
A slow i.v. infusion of oxytocin (,2 U/min), which avoids systemic
hypotension, is administered after placental delivery to prevent
maternal haemorrhage. Prostaglandin F analogues are useful to
treat post-partum haemorrhage, unless an increase in pulmonary
artery pressure (PAP) is undesirable. Methylergonovine is contra-
indicated because of the risk (.10%) of vasoconstriction and
hypertension.62,63 Meticulous leg care, elastic support stockings,
and early ambulation are important to reduce the risk of
thrombo-embolism. Delivery is associated with important haemo-
dynamic changes and fluid shifts, particularly in the first 12–24 h,
which may precipitate heart failure in women with structural
heart disease. Haemodynamic monitoring should therefore be
continued for at least 24 h after delivery.64
Breastfeeding
Lactation is associated with a low risk of bacteraemia secondary to
mastitis. In highly symptomatic/unwell patients, bottle-feeding
should be considered.
2.10 Infective endocarditis
Infective endocarditis during pregnancy is rare, with an estimated
overall incidence of 0.006% (1 per 100 000 pregnancies)65 and
an incidence of 0.5% in patients with known valvular or congenital
heart disease.66 The incidence is higher in drug addicts. Patients
with the highest risk for infective endocarditis are those with a
prosthetic valve or prosthetic material used for cardiac valve
repair, a history of previous infective endocarditis, and some
special patients with congenital heart disease.
2.10.1 Prophylaxis
The same measures as in non-pregnant patients with recent modi-
fications of guidelines apply.67 Endocarditis prophylaxis is now only
recommended for patients at highest risk of aquiring endocarditis
during high risk procedures, e.g. dental procedures. During delivery
the indication for prophylaxis has been controversial and, given the
lack of convincing evidence that infective endocarditis is related to
either vaginal or caesarean delivery, antibiotic prophylaxis is not
recommended during vaginal or caesarean delivery.67,68
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2.10.2 Diagnosis and risk assessment
The diagnosis of infective endocarditis during pregnancy involves
the same criteria as in the non-pregnant patient.67 In spite of pro-
gress in the diagnosis and treatment of infective endocarditis,
maternal morbidity and mortality remain high, reportedly 33% in
one study (mainly due to heart failure and thrombo-embolic com-
plications).69 Fetal mortality is also high at 29%. Heart failure due
to acute valve regurgitation is the most common complication,
requiring urgent surgery when medical treatment cannot stabilize
the patient.67 Cerebral and peripheral embolizations are also fre-
quent complications.
2.10.3 Treatment
Infective endocarditis should be treated the same way as in the
non-pregnant patient, bearing in mind the fetotoxic effects of anti-
biotics (see Section 11). If infective endocarditis is diagnosed, anti-
biotics should be given guided by culture and antibiotic sensitivity
results and local treatment protocols. Antibiotics that can be given
during all trimesters of pregnancy are penicillin, ampicillin, amoxi-
cillin, erythromycin, mezlocillin, and cephalosporins.70 All of
them are included in group B of the Food and Drug Administration
(FDA) classification. Vancomycin, imipenem, rifampicin, and teico-
planin are all group C, which means risk cannot be excluded and
their risk–benefit ratio must be carefully considered. There is a
definite risk to the fetus in all trimesters of pregnancy with
group D drugs (aminoglycosides, quinolones, and tetracyclines)
and they should therefore only be used for vital indications.71
Valve surgery during pregnancy should be reserved for cases
where medical therapy has failed as per guidelines in non-pregnant
patients.67 A viable fetus should be delivered prior to surgery
where possible (see Section 2.8.2).
2.11 Risk estimation: contraindications
for pregnancy
2.11.1 Pre-pregnancy counselling
The risk of pregnancy depends on the specific heart disease and
clinical status of the patient. Individual counselling by experts is rec-
ommended. Adolescents should be given advice on contraception,
and pregnancy issues should be discussed as soon as they become
sexually active. A risk assessment should be performed prior to
pregnancy and drugs reviewed so that those which are contraindi-
cated in pregnancy can be stopped or changed to alternatives
where possible (see Section 11.2, Table 21). The follow-up plan
should be discussed with the patient and, if possible, her partner.
Women with significant heart disease should be managed jointly
by an obstetrician and a cardiologist with experience in treating
pregnant patients with heart disease from an early stage. High
risk patients should be managed by an expert multidisciplinary
team in a specialist centre. All women with heart disease should
be assessed at least once before pregnancy and during pregnancy,
and hospital delivery should be advised.
2.11.2 Risk assessment: estimation of maternal and
offspring risk
To estimate the risk of maternal cardiovascular complications,
several approaches are available. Disease-specific risk can be
assessed, and is described in these guidelines in the respective
sections dealing with specific diseases. In general, the risk of com-
plications increases with increasing disease complexity.56,72
Disease-specific series are usually retrospective and too small to
identify predictors of poor outcome. Therefore, risk estimation can
be further refined by taking into account predictors that have been
identified in studies that included larger populations with various dis-
eases. Several risk scores have been developed based on these predic-
tors, of which the CARPREG risk score is most widely known and
used. This risk score has been validated in several studies and
Table 4 Predictors of maternal cardiovascular events
and risk score from the CARPREG study12
Prior cardiac event (heart failure, transient ischaemic attack, stroke 
before pregnancy or arrhythmia).
Baseline NYHA functional class >II or cyanosis.
Left heart obstruction (mitral valve area <2 cm2, aortic valve area 
<1.5 cm2, peak LV outflow tract gradient >30 mmHg by 
echocardiography).
Reduced systemic ventricular systolic function (ejection fraction 
<40%).
CARPREG risk score: for each CARPREG predictor that is present a point is




LV ¼ left ventricular; NYHA ¼ New York Heart Association.
Table 5 Predictors of maternal cardiovascular events
identified in congential heart diseases in the ZAHARA
and Khairy study
ZAHARA predictors57
History of arrhythmia event.
Baseline NYHA functional class >II.
Left heart obstruction (aortic valve peak gradient >50 mm Hg).
Mechanical valve prosthesis.
Moderate/severe systemic atrioventricular valve regurgitation (possibly 
related to ventricular dysfunction). 
Moderate/severe sub-pulmonary atrioventricular valve regurgitation 
(possibly related to ventricular dysfunction).
Use of cardiac medication pre-pregnancy.
Repaired or unrepaired cyanotic heart disease.
Predictors from Khairy76
Smoking history.
Reduced subpulmonary ventricular function and/or severe pulmonary 
regurgitation.
NYHA ¼ New York Heart Association.
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appears valuable to predict maternal risk, although overestimation
can occur.57,73 The CARPREG risk score is described in Table 4. In
women with congenital heart disease, the CARPREG score12 may
also be associated with a higher risk of late cardiovascular events post-
pregnancy.74 The predictors from the ZAHARA study57 (Table 5)
have not yet been validated in other studies. It should be noted that
predictors and risk scores from the CARPREG and ZAHARA
studies are highly population dependent. Important risk factors
including pulmonary arterial hypertension (PAH) and dilated aorta
were not identified because they were under-represented in these
studies. The CARPREG study included acquired and congenital
heart disease, while the ZAHARA study investigated a population
with congenital heart disease only.
The Task Force recommends that maternal risk assessment is
carried out according to the modified World Health Organization
(WHO) risk classification.72 This risk classification integrates all
known maternal cardiovascular risk factors including the underlying
heart disease and any other co-morbidity. It includes contraindica-
tions for pregnancy that are not incorporated in the CARPREG
and ZAHARA risk scores/predictors. The general principles of
this classification are depicted in Table 6. A practical application
is given in Table 7. In women in WHO class I, risk is very low,
and cardiology follow-up during pregnancy may be limited to
one or two visits. Those in WHO II are at low or moderate risk,
and follow-up every trimester is recommended. For women in
WHO class III, there is a high risk of complications, and frequent
(monthly or bimonthly) cardiology and obstetric review during
pregnancy is recommended. Women in WHO class IV should be
advised against pregnancy but, if they become pregnant and will
not consider termination, monthly or bimonthly review is needed.
Neonatal complications occur in 20–28% of patients with heart
disease12,56,57,75,76 with a neonatal mortality between 1% and
4%.12,56,57 Maternal and neonatal events are highly correlated.57
Predictors of neonatal complications are listed in Table 8.
Table 7 Modified WHO classification of maternal
cardiovascular risk: application
Conditions in which pregnancy risk is WHO I
• Uncomplicated, small or mild 
 - pulmonary stenosis
 - patent ductus arteriosus
 - mitral valve prolapse
• Successfully repaired simple lesions (atrial or ventricular septal 
 defect, patent ductus arteriosus, anomalous pulmonary venous 
 drainage).
• Atrial or ventricular ectopic beats, isolated
Conditions in which pregnancy risk is WHO II or III
WHO II (if otherwise well and uncomplicated) 
• Unoperated atrial or ventricular septal defect 
• Repaired tetralogy of Fallot
• Most arrhythmias
WHO II–III (depending on individual)
• Mild left ventricular impairment
• Hypertrophic cardiomyopathy
• Native or tissue valvular heart disease not considered WHO I or IV
• Marfan syndrome without aortic dilatation




• Systemic right ventricle 
• Fontan circulation
• Cyanotic heart disease (unrepaired)
• Other complex congenital heart disease 
• Aortic dilatation 40–45 mm in Marfan syndrome
• Aortic dilatation 45–50 mm in aortic disease associated with bicuspid 
 aortic valve
Conditions in which pregnancy risk is WHO IV 
(pregnancy contraindicated)
• Pulmonary arterial hypertension of any cause
• Severe systemic ventricular dysfunction (LVEF <30%, NYHA III–IV)
• Previous peripartum cardiomyopathy with any residual impairment of 
 left ventricular function
• Severe mitral stenosis, severe symptomatic aortic stenosis
• Marfan syndrome with aorta dilated >45 mm
• Aortic dilatation >50 mm in aortic disease associated with bicuspid 
 aortic valve
• Native severe coarctation 
Adapted from Thorne et al.73
LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association;
WHO ¼World Health Organization.
Table 6 Modified WHO classification of maternal
cardiovascular risk: principles
Risk class Risk of pregnancy by medical condition
I
No detectable increased risk of maternal mortality and 
no/mild increase in morbidity.
II
Small increased risk of maternal mortality or moderate 
increase in morbidity.
III
Significantly increased risk of maternal mortality 
or severe morbidity. Expert counselling required. 
If pregnancy is decided upon, intensive specialist 
cardiac and obstetric monitoring needed throughout 
pregnancy, childbirth, and the puerperium.
IV
Extremely high risk of maternal mortality or severe 
morbidity; pregnancy contraindicated. If pregnancy 
occurs termination should be discussed. If pregnancy 
continues, care as for class III.
Modified from Thorne et al.72
WHO ¼World Health Organization
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2.12 Methods of contraception and
termination of pregnancy, and in vitro
fertilization
2.12.1 Methods of contraception
Contraceptive methods include combined hormonal contracep-
tives (oestrogen/progestin), progestogen-only methods, intrauter-
ine devices, and emergency contraception. Their use needs to be
balanced against the risk of pregnancy.
In 2010, the Centers for Disease Control (CDC) modified the
WHO suggestions for medical eligibility criteria for contraceptive
use in women with CVD. [http://www.cdc.gov/Mmwr/preview/
mmwrhtml/rr59e0528a13.htm]. Monthly injectables that contain
medroxyprogesterone acetate are inappropriate for patients with
heart failure because of the tendency for fluid retention. Low
dose oral contraceptives containing 20 mg of ethinyl estradiol are
safe in women with a low thrombogenic potential, but not in
women with complex valvular disease.77,78
Apart from barrier methods (condom), the levonorgestrel-
releasing intrauterine device is the safest and most effective contra-
ceptive that can be used in women with cyanotic congenital heart
disease and pulmonary vascular disease. It reduces menstrual
blood loss by 40–50% and induces amenorrhoea in a significant pro-
portion of users.79 It should be borne in mind that 5% of patients
experience vasovagal reactions at the time of implant; therefore, for
those with highly complex heart disease (e.g. Fontan, Eisenmenger)
intrauterine implants are indicated only when progesterone-only
pills or dermal implants have proved unacceptable and, if used,
they should only be implanted in a hospital environment. A copper
intrauterine device is acceptable in non-cyanotic or mildly cyanotic
women. Antibiotic prophylaxis is not recommended at the time of
insertion or removal since the risk of pelvic infection is not increased.
If excessive bleeding occurs at the time of menses, the device should
be removed. It is contraindicated in cyanotic women with haemato-
crit levels .55% because intrinsic haemostatic defects increase the
risk of excessive menstrual bleeding.
2.12.2 Sterilization
Tubal ligation is usually accomplished safely, even in relatively high
risk women. Because of the associated anaesthesia and abdominal
inflation, it is, however, not without risk in patients with PAH, cya-
nosis, and Fontan circulation. The risk may be lower with the mini-
mally invasive hysteroscopic techniques such as the Essure device.
Hysteroscopic sterilization is performed by inserting a metal
micro-insert or polymer matrix into the interstitial portion of
each fallopian tube. Three months after placement, correct
device placement and bilateral tubal occlusion are confirmed
with pelvic imaging. Advantages of hysteroscopic sterilization
include the ability to perform the procedure in an outpatient
setting and without an incision. A disadvantage is the 3 month
waiting period until tubal occlusion is confirmed.80 Vasectomy
for the male partner is another efficacious option, but the long-
term prognosis of the female partner must be taken into
account as the male partner may outlive her for many years.
Given the lack of published data about contraception in heart
disease, advice should be provided by physicians or gynaecologists
with appropriate training.
2.12.3 Methods of termination of pregnancy
Pregnancy termination should be discussed with women in whom
gestation represents a major maternal or fetal risk. The first trime-
ster is the safest time for elective pregnancy termination, which
should be performed in hospital, rather than in an outpatient facil-
ity, so that all emergency support services are available. The
method, including the need for anaesthesia, should be considered
on an individual basis. High risk patients should be managed in an
experienced centre with on-site cardiac surgery. Endocarditis pro-
phylaxis is not consistently recommended by cardiologists,81 but
treatment should be individualized. Gynaecologists routinely
advise antibiotic prophylaxis to prevent post-abortal endometritis,
which occurs in 5–20% of women not given antibiotics.82,83
Dilatation and evacuation is the safest procedure in both the
first and second trimesters. If surgical evacuation is not feasible
in the second trimester, prostaglandins E1 or E2, or misoprostol,
a synthetic prostaglandin structurally related to prostaglandin E1,
can be administered to evacuate the uterus.84 These drugs are
absorbed into the systemic circulation and can lower systemic vas-
cular resistance and BP, and increase heart rate, effects that are
greater with E2 than with E1.
85
Up to 7 weeks gestation, mifepristone is an alternative to
surgery. When prostaglandin E compounds are given, systemic
arterial oxygen saturation should be monitored with a transcu-
taneous pulse oximeter and norepinephrine infused at a rate that
supports the DBP, which reflects systemic vascular resistance.
Prostaglandin F compounds should be avoided because they can
significantly increase PAP and may decrease coronary perfusion.85
Saline abortion should be avoided because saline absorption can
cause expansion of the intravascular volume, heart failure, and clot-
ting abnormalities.
2.12.4 In vitro fertilization
In vitro fertilization may be considered where the risk of the pro-
cedure itself, including hormonal stimulation and pregnancy, is low.
Thrombo-embolism may complicate in vitro fertilization when high
oestradiol levels may precipitate a prothrombotic state.86
Table 8 Maternal predictors of neonatal events in
women with heart disease
1. Baseline NYHA class >II or cyanosis 12
2. Maternal left heart obstruction 12,76
3. Smoking during pregnancy 12,57
4. Multiple gestation 12,57
5. Use of oral anticoagulants during pregnancy 12
6. Mechanical valve prosthesis 57
Modified from Siu et al.12 (CARPREG investigators); Khairy et al.76; Drenthen/
Pieper et al.57 (ZAHARA investigators).
NYHA ¼ New York Heart Association.
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2.13 General recommendations 3. Congenital heart disease and
pulmonary hypertension
In many women with congenital heart disease, pregnancy is well
tolerated. The risk of pregnancy depends on the underlying
heart disease as well as on additional factors such as ventricular
and valvular function, functional class, and cyanosis. The miscar-
riage rate is higher in more complex disease (Figure 1).56 Maternal
cardiac complications are present in 12% of completed pregnan-
cies and are again more frequent as the disease becomes more
complex. Patients who experience complications during pregnancy
may also be at higher risk of late cardiac events after pregnancy.74
Offspring complications, including offspring mortality (4%), are
more frequent than in the general population.
Diagnosis
Usually, congenital heart diseases will be known and diagnosed
before pregnancy. Pre-pregnancy assessment including medical
history, echocardiography, and exercise testing is indicated in all
patients, with other diagnostic tests indicated on an individual
patient basis. Functional status before pregnancy and history of
previous cardiac events are of particular prognostic value (see
Tables 4 and 5). Also B-type natriuretic peptide (BNP)/N-terminal
pro B-type natriuretic peptide (NT-pro-BNP) assessment may be
helpful in risk stratification. An exercise test before pregnancy
achieving ,70% of expected workload, showing a drop in arterial
pressure or a drop in oxygen saturation may identify women at
risk of developing symptoms or complications during pregnancy.
Diagnostic procedures that can be used during pregnancy are
outlined in Section 2.6.21 For further risk assessment see
Section 2.11.
3.1 Maternal high risk conditions [World
Health Organization (III)–IV; see also
Section 2.11]
Patients in NYHA class III/IV or with severely reduced function of
the systemic ventricle are at high risk during pregnancy, along with
other specific conditions discussed below. In addition, some
specific conditions are at particular high risk during pregnancy.
3.1.1 Pulmonary hypertension
Maternal risk
Pulmonary hypertension encompasses a group of diseases with
different pathophysiologies which include PAH, pulmonary hyper-
tension related to left heart disease, pulmonary hypertension
related to lung disease and/or hypoxia, chronic thrombo-embolic
pulmonary hypertension, and pulmonary hypertension with
unclear and or multifactorial mechanisms. PAH includes the idio-
pathic and heritable forms of the disease as well as pulmonary
hypertension associated with congenital heart disease, with or
without previous corrective surgery. A mean PAP ≥25 mmHg at
rest is indicative of pulmonary hypertension.87 A high maternal
mortality risk is reported (30–50% in older series and 17–33%
Table 9 General recommendations
Recommendations Classa Levelb
Pre-pregnancy risk assessment and counselling 
is indicated in all women with known or 
suspected congenital or acquired cardiovascular 
and aortic disease. 
I C
Risk assessment should be performed in all 
women with cardiac diseases of childbearing 
age and after conception.
I C
High risk patients should be treated in 
specialized centres by a multidisciplinary team. I C
Genetic counselling should be offered to women 
with congenital heart disease or congenital 
arrhythmia, cardiomyopathies, aortic disease or 
genetic malformations associated with CVD.
I C
Echocardiography should be performed in 
any pregnant patient with unexplained or new 
cardiovascular signs or symptoms.
I C
Before cardiac surgery a full course of 
corticosteroids should be administered to the 
mother whenever possible. 
I C
For the prevention of infective endocarditis 
in pregnancy the same measures as in non-
pregnant patients should be used.
I C
Vaginal delivery is recommended as first choice 
in most patients. I C
MRI (without gadolinium) should be considered 
if echocardiography is insufficient for diagnosis. IIa C
In patients with severe hypertension, vaginal 
delivery with epidural analgesia and elective 
instrumental delivery should be considered.
IIa C
When gestational age is at least 28 weeks, 
delivery before necessary surgery should be 
considered. 
IIa C
Caesarean delivery should be considered for 
obstetric indications or for patients with 
dilatation of the ascending aorta >45 mm, 
severe aortic stenosis, pre-term labour while on 
oral anticoagulants, Eisenmenger syndrome, or 
severe heart failure.
IIa C
Caesarean delivery may be considered in Marfan 
patients with an aortic diameter 40–45mm. IIb C
A chest radiograph, with shielding of the fetus, 
may be considered if other methods are not 
successful in clarifying the cause of dyspnoea.
IIb C
Cardiac catheterization may be considered with 
very strict indications, timing, and shielding of
the fetus.
IIb C
CT and electrophysiological studies, with 
shielding of the fetus, may be considered in 
selected patients for vital indications. 
IIb C
Coronary bypass surgery or valvular surgery 
may be considered when conservative and 
medical therapy has failed, in situations that 
threaten the mother’s life and that are not 
amenable to percutaneous treatment.
IIb C
Prophylactic antibiotic therapy during delivery is 
not recommended. III C
aClass of recommendation.
bLevel of evidence.
CT ¼ computed tomography; CVD ¼ cardiovascular disease; MRI ¼ magnetic
resonance imaging
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in more recent papers) in patients with severe PAH and Eisenmen-
ger syndrome.87,88 Maternal death occurs in the last trimester of
pregnancy and in the first months after delivery because of pul-
monary hypertensive crises, pulmonary thrombosis, or refractory
right heart failure. This occurs even in patients with little or no dis-
ability before or during pregnancy. Risk factors for maternal death
are: late hospitalization, severity of pulmonary hypertension, and
general anaesthesia.87 The risk probably increases with more elev-
ated pulmonary pressures. However, even moderate forms of pul-
monary vascular disease can worsen during pregnancy as a result
of the decrease in systemic vascular resistance and overload of
the right ventricle, and no safe cut-off value is known. Whether
the risk is also high for congenital patients after successful shunt
closure with mildly elevated pulmonary pressures [e.g. after atrial
septal defect (ASD) closure with a mean pressure of 30 mmHg]
is not well known, but these risks are probably lower and preg-
nancy can be considered after a careful risk assessment on the
basis of all available diagnostic modalities in a specialized centre.89
Obstetric and offspring risk
Neonatal survival rates are reported to be 87–89%.87
Management
Follow-up. If pregnancy occurs, termination should be offered. In
view of the risks of anaesthesia this should be performed in a
tertiary centre experienced in the management of PAH patients.
If patients choose to continue pregnancy despite the risk, they
should be managed in a centre with expertise in PAH with all
therapeutic options available.68 Every effort should be made to
maintain circulating volume, and to avoid systemic hypotension,
hypoxia, and acidosis which may precipitate refractory heart
failure. Supplemental oxygen therapy should be given if there is
hypoxaemia. I.v. prostacyclin or aerosolized iloprost have been
occasionally used antenatally and peripartum to improve haemody-
namics during delivery.90 In patients who are already taking drug
therapy for PAH before becoming pregnant, continuation of this
therapy should be considered, but patients should be informed
about the teratogenic effects of some therapies, such as bosentan.
Haemodynamic monitoring by Swan–Ganz catheter may be
associated with serious complications such as pulmonary artery
rupture, while its utility has not been demonstrated; therefore, it
is rarely if ever indicated.
Medical therapy. In patients where the indication for anticoagulation
outside pregnancy is established, anticoagulation should also be
maintained during pregnancy.89 In PAH associated with congenital
cardiac shunts in the absence of significant haemoptysis, anticoagu-
lant treatment should be considered in patients with pulmonary
artery thrombosis or signs of heart failure. In PAH associated
with connective tissue disorders, anticoagulant treatment should
be considered on an individual basis. In PAH associated with
portal hypertension, anticoagulation is not recommended in























































Figure 1 Distribution of miscarriages, completed pregnancies (.20 weeks pregnancy duration), and elective abortions for each congenital
heart disease separately and the overall rates. ASD ¼ atrial septal defect; AVSD ¼ atrioventricular septal defect; AOS ¼ aortic stenosis;
CC-TGA ¼ congenital corrected transposition of the great arteries; CHD ¼ congenital heart disease; Coarctation ¼ aortic coarctation;
Ebstein ¼ Ebstein’s anomaly; Eisenmenger ¼ Eisenmenger syndrome; Fontan ¼ patients after Fontan repair; PAVSD ¼ pulmonary atresia
with ventricular septal defects; PS ¼ pulmonary valve stenosis; TGA ¼ complete transposition of the great arteries; TOF ¼ tetralogy of
Fallot; VSD ¼ ventricular septal defect.
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The type of anticoagulation during pregnancy (UFH vs. LMWH)
needs to be decided on an individual basis. Randomized studies
comparing the effectiveness of different heparins are not available;
neither are studies available concerning the risks associated with
replacement of OACs during the pregnancy by either UFH or
LMWH. A risk assessment concerning the type of anticoagulation
chosen should be performed. Because of the increased risk of
bleeding in these patients, subcutaneous application of LMWH
or UFH is favoured over oral anticoagulation during pregnancy. It
should be recognized that potentially significant drug interactions
with PAH-targeted therapies may occur, and careful monitoring
of anticoagulation is necessary [INR monitoring with OACs; acti-
vated partial thromboplastin time (aPTT) monitoring in the case
of UFH; anti-Xa levels in the case of LMWH].
Delivery. The mode of delivery should be individualized. Planned
caesarean delivery and vaginal delivery are favoured over emer-
gency caesarean delivery.
3.1.2 Patients with the ‘Eisenmenger syndrome’
Maternal risk
Eisenmenger patients need special consideration because of the
association of pulmonary hypertension with cyanosis due to the
right-to-left shunt. Systemic vasodilatation increases the
right-to-left shunt and decreases pulmonary flow, leading to
increased cyanosis and eventually to a low output state. The litera-
ture reports a high maternal mortality of 20–50%, occurring most
often in the peri- or post-partum period.91
Obstetric and offspring risk
Cyanosis poses a significant risk to the fetus, with a live birth unli-
kely (,12%) if oxygen saturation is ,85%.
Management
Follow-up. When pregnancy occurs, the risks should be discussed
and a termination of pregnancy offered; however, termination
also carries a risk.68 If the patient wishes to continue with preg-
nancy, care should be based in a specialist unit. Bed rest may be
beneficial. Thrombo-embolism is a major risk for cyanotic patients,
therefore patients should be considered for prophylaxis after hae-
matology review and investigations for blood haemostasis. Antic-
oagulation must be used with caution, as patients with
Eisenmenger syndrome are also prone to haemoptysis and throm-
bocytopenia. The risks and benefits of anticoagulation must there-
fore be carefully considered on an individual patient basis. In
patients with heart failure, diuretics must be used judiciously and
at the lowest effective dose to avoid haemoconcentration and
intravascular volume depletion. Microcytosis and iron deficiency
are frequent and should be treated with supplemental oral or i.v.
iron, avoiding a rebound effect. Frequent clinical review with
oxygen saturation measurement and full blood count are indicated.
Delivery. If the maternal or fetal condition deteriorates, an early
caesarean delivery should be planned. In view of the risks of anaes-
thesia this should be performed in a tertiary centre experienced in
the management of these patients. In others, timely hospital admis-
sion, planned elective delivery, and incremental regional anaesthe-
sia may improve maternal outcome.68
3.1.3 Cyanotic heart disease without pulmonary
hypertension
Maternal risk
Cyanotic congenital heart disease is usually corrected before preg-
nancy, but some inoperable or palliated cases do reach childbear-
ing age. Maternal complications (heart failure, pulmonary or
systemic thrombosis, supraventricular arrhythmias, infective endo-
carditis) occur in 30% of cyanotic pregnant patients. If resting
oxygen saturation is ,85%, a substantial maternal and fetal mor-
tality risk is expected and pregnancy is contraindicated. If resting
oxygen saturation is 85–90% it is advisable to measure it during
exercise. If the saturation decreases significantly and early, patients
should be advised that pregnancy has a poor prognosis.
Obstetric and offspring risk
The degree of maternal hypoxaemia is the most important predic-
tor of fetal outcome. With resting maternal blood saturation
.90%, fetal outcome is good (,10% fetal loss). If, however,
maternal oxygen saturation is ,85%, the chance of a live birth is
12% and pregnancy should therefore be discouraged.91
Management
Follow-up. During pregnancy, restriction of physical activity and sup-
plemental oxygen (monitoring oxygen saturation) are rec-
ommended. Because of the increased risk of paradoxical
embolism, prevention of venous stasis (use of compression stock-
ings and avoiding the supine position) is important. For prolonged
bed rest, prophylactic heparin administration should be con-
sidered. Haematocrit and haemoglobin levels are not reliable indi-
cators of hypoxaemia. Thrombo-embolism is a major risk for
cyanotic patients, therefore patients should be considered for pro-
phylaxis after haematology review and investigations for blood
haemostasis.
Medical therapy. LMWH thromboprophylaxis should be considered
if blood haemostasis is normal. Diuretics and iron therapy are indi-
cated and managed in the same way as in patients with Eisenmen-
ger syndrome.
Delivery. Vaginal delivery is advised in most cases. If the maternal or
fetal condition deteriorates, an early caesarean delivery should be
planned. In view of the risks of anaesthesia this should be per-
formed in a tertiary centre experienced in the management of
these patients. In others, timely hospital admission, planned elec-
tive delivery, and incremental regional anaesthesia may improve
maternal outcome.68
3.1.4 Severe left ventricular outflow tract obstruction
Severe symptomatic left ventricular outflow tract obstruction
(LVOTO) is a contraindication for pregnancy and should be
treated before pregnancy, or women should be counselled
against pregnancy. It may be valvular, supravalvular, or caused by
discrete membranous or tunnel-type subvalvular AS. The manage-
ment of supravalvular and subvalvular stenosis is only described in
case reports during pregnancy and is probably similar to the man-
agement of patients with valvular stenosis, although balloon valvu-
lotomy is not a therapeutic option.92 The management of
pregnancy in (severe) AS is described in the section on valvular
heart disease (Section 5).
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3.2 Maternal low and moderate risk
conditions (World Health Organization I,
II, and III; see also Tables 6 and 7)
In patients who have undergone previous successful surgical repair
without mechanical heart valve implantation, pregnancy is often
well tolerated if exercise tolerance is good, ventricular function
is normal, and functional status is good. Although patients need
to be informed about the (often small) additional risk, pregnancy
should not be discouraged. Patients should be seen by the end
of the first trimester and a follow-up plan with time intervals for
review and investigations such as echocardiograms defined. The
follow-up plan should be individualized taking into account the
complexity of the heart disease and clinical status of the patient.
Some congenital conditions may deteriorate during pregnancy,
therefore follow-up timelines need to be flexible. Vaginal delivery
can be planned in most cases.3,93,94
3.3 Specific congenital heart defects
3.3.1 Atrial septal defect
Maternal risk
Pregnancy is well tolerated by most women with an ASD. The only
contraindication is the presence of PAH or Eisenmenger syndrome
(see Sections 3.2.1 and 3.2.2).95 Closure of a haemodynamically sig-
nificant ASD should be performed before pregnancy.
Thrombo-embolic complications have been described in up to
5%.56 Arrhythmias occur more often than in healthy women,
especially when the ASD is unrepaired or closed at older age
and the pregnant woman is .30 years old.95,96
Obstetric and offspring risk
In women with unrepaired ASD, pre-eclampsia and small for gesta-
tional age births may occur more frequently. In repaired ASD, no
extra risk is encountered.
Management
Usually follow-up twice during pregnancy is sufficient. For a secun-
dum defect, catheter device closure can be performed during preg-
nancy, but is only indicated when the condition of the mother is
deteriorating (with transoesophageal or intracardiac echocardio-
graphic guidance). Closure of a small ASD or persistent foramen
ovale for the prevention of paradoxical emboli is not indicated.
Because of the increased risk of paradoxical embolism, in
women with a residual shunt, prevention of venous stasis (use of
compression stockings and avoiding the supine position) is impor-
tant, as is early ambulation after delivery. For prolonged bed rest,
prophylactic heparin administration should be considered.97 Dili-
gent care is important to eliminate air in i.v. lines which could
lead to systemic embolization due to right-to-left shunting during
labour.
Spontaneous vaginal delivery is in most cases appropriate.
3.3.2 Ventricular septal defect
Maternal risk
For large ventricular septal defects (VSDs) with pulmonary hyper-
tension, see maternal high risk conditions (Section 3.1). Small peri-
membranous VSDs (without left heart dilatation) have a low risk of
complications during pregnancy.98 Corrected VSDs have a good
prognosis during pregnancy, when LV function is preserved. Pre-
pregnancy evaluation of the presence of a (residual) defect,
cardiac dimensions, and an estimation of pulmonary pressures is
recommended.
Obstetric and offspring risk
Pre-eclampsia may occur more often than in the normal
population.98
Management
Usually follow-up twice during pregnancy is sufficient and spon-
taneous vaginal delivery is appropriate.
3.3.3 Atrioventricular septal defect
Maternal risk
After correction, pregnancy is usually well tolerated when residual
valve regurgitation is not severe and ventricular function is normal
(WHO risk class II). Patients with severe (residual) left atrioventri-
cular (AV) valve regurgitation with symptoms and/or impaired ven-
tricular function should be treated surgically pre-pregnancy,
favouring valve repair.7 For atrioventricular septal defect (AVSD)
with pulmonary hypertension, see maternal high risk conditions
(Section 3.1.1). Correction of a haemodynamically significant
AVSD before pregnancy should be considered.19 Arrhythmias
and worsening of NYHA class as well as worsening of AV valve
regurgitation have been described during pregnancy.99 The risk
of heart failure is low and only exists in women with severe regur-
gitation or impaired ventricular function.
Obstetric and offspring risk
Obstetric complications are mainly related to the risk of acute
heart failure during or just after delivery and they depend on symp-
toms and PAP during pregnancy. Offspring mortality has been
reported in 6%, primarily due to the occurrence of complex con-
genital heart disease.99
Management
Follow-up. Follow-up during pregnancy is advisable at least once
each trimester. Clinical and echocardiographic follow-up is indi-
cated monthly or bimonthly in patients with moderate or severe
valve regurgitation or impaired ventricular function. In uncorrected
AVSD, the risk of paradoxical embolization exists. For rec-
ommended preventive measures for thrombo-embolism, see
Section 3.3.1.
Delivery. Spontaneous vaginal delivery is appropriate in most cases.
3.3.4 Coarctation of the aorta
Maternal risk
Pregnancy is often well tolerated in women after repair of coarcta-
tion of the aorta (CoA) (WHO risk class II). Significant (re)
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coarctation should be corrected before pregnancy. Women with
unrepaired native CoA and those repaired who have residual
hypertension, residual CoA, or aortic aneurysms have an increased
risk of aortic rupture and rupture of a cerebral aneurysm during
pregnancy and delivery. Other risk factors for this complication
include aortic dilatation and bicuspid aortic valve, and they
should be looked for pre-pregnancy.
Obstetric and offspring risk
An excess of hypertensive disorders and miscarriages has been
reported.100,101
Management
Close surveillance of BP is warranted, and regular follow-up at least
every trimester is indicated. Hypertension should be treated,
although aggressive treatment in women with residual coarctation
must be avoided to prevent placental hypoperfusion. Percutaneous
intervention for re-CoA is possible during pregnancy, but it is
associated with a higher risk of aortic dissection than outside preg-
nancy and should only be performed if severe hypertension per-
sists despite maximal medical therapy and there is maternal or
fetal compromise. The use of covered stents may lower the risk
of dissection.
Delivery. Spontaneous vaginal delivery is preferred with use of epi-
dural anaesthesia particularly in hypertensive patients.
3.3.5 Pulmonary valve stenosis and regurgitation
Maternal risk
Pulmonary valve stenosis (PS) is generally well tolerated during
pregnancy.102 –104 However, severe stenosis may result in compli-
cations including right ventricular (RV) failure and arrhythmias. Pre-
pregnancy relief of stenosis (usually by balloon valvuloplasty)
should be performed in severe stenosis (peak Doppler gradient
.64 mmHg).19,68,105
Severe pulmonary regurgitation has been identified as an inde-
pendent predictor of maternal complications, especially in patients
with impaired ventricular function.76,106 In symptomatic women or
when RV function is abnormal due to severe pulmonary regurgita-
tion, pre-pregnancy pulmonary valve replacement (preferably bio-
prosthesis) should be considered.
Obstetric and offspring risk
The incidence of maternal obstetric complications, particularly
hypertension-related disorders including (pre-)eclampsia, may be
increased in women with PS.103 The incidence of offspring compli-
cations also appears to be higher than in the general population.103
Pulmonary regurgitation generally carries no additional offspring
risk.
Management
Follow-up. Mild and moderate PS are regarded low-risk lesions
(WHO risk classes I and II) (Tables 6 and 7), and follow-up once
every trimester is sufficient. In patients with severe PS, monthly
or bimonthly cardiac evaluations including echocardiography are
advised to determine clinical status and for surveillance of RV func-
tion. During pregnancy in severely symptomatic PS not responding
to medical therapy and bed rest, percutaneous valvuloplasty can be
undertaken.
Delivery. Vaginal delivery is favoured in patients with non-severe PS,
or severe PS in NYHA class I/II. Caesarean section is considered in
patients with severe PS and in NYHA class III/IV despite medical
therapy and bed rest, in whom percutaneous pulmonary valvot-
omy cannot be performed or has failed.
3.3.6 Aortic stenosis
Congenital AS is most often caused by a bicuspid aortic valve. The
rate of progression of stenosis in these young patients is lower
than in older patients.107 Because bicuspid aortic valve is associated
with aortic dilatation and aortic dissection, aortic dimensions
should be measured pre-pregnancy and during pregnancy. The
risk of dissection is increased during pregnancy (see also Section
4.3).108,109 All women with a bicuspid aortic valve should
undergo imaging of the ascending aorta before pregnancy, and
surgery should be considered when the aortic diameter is
.50 mm. For recommendations on the management of pregnant
women with AS, see Section 5 on valvular heart disease.
3.3.7 Tetralogy of Fallot
Maternal risk
In unrepaired patients, surgical repair is indicated before preg-
nancy. Women with repaired tetralogy of Fallot usually tolerate
pregnancy well (WHO risk class II). Cardiac complications during
pregnancy have been reported in up to 12% of patients. Arrhyth-
mias and heart failure in particular may occur.110 Other compli-
cations include thrombo-embolism, progressive aortic root
dilatation, and endocarditis. Dysfunction of the right ventricle
and/or moderate to severe pulmonary regurgitation are risk
factors for cardiovascular complications, and pregnancy may be
associated with a persisting increase in RV size. In symptomatic
women with marked dilatation of the right ventricle due to
severe pulmonary regurgitation, pre-pregnancy pulmonary valve
replacement (homograft) should be considered.19
Obstetric and offspring risk
The risk of offspring complications is increased.
Management
Follow-up. Follow-up every trimester is sufficient in the majority of
women. In women with severe pulmonary regurgitation, monthly
or bimonthly cardiac evaluation with echocardiography is indi-
cated. If RV failure occurs during pregnancy, treatment with diure-
tics should be started and bed rest advised. Transcatheter valve
implantation or early delivery should be considered in those
who do not respond to conservative treatment.




In women with Ebstein’s anomaly without cyanosis and heart
failure, pregnancy is often tolerated well (WHO risk classII). Symp-
tomatic patients with cyanosis and/or heart failure should be
treated before pregnancy or counselled against pregnancy. In
severe symptomatic tricuspid regurgitation (TR), repair should be
considered pre-pregnancy. The haemodynamic problems seen
during pregnancy depend largely on the severity of the TR and
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the functional capacity of the right ventricle.111,112 An ASD and
also the Wolff–Parkinson–White syndrome are common associ-
ated findings. The incidence of arrhythmias may rise during preg-
nancy and is associated with a worse prognosis.111
Obstetric and offspring risk
The risk of premature delivery and fetal mortality is elevated.112
Management
Follow-up. Even severe TR with heart failure can usually be managed
medically during pregnancy. Women with Ebstein’s anomaly and
interatrial shunting can develop shunt reversal and cyanosis in
pregnancy. There is also a risk of paradoxical emboli (see
Section 3.4.2).
Delivery. The preferred mode of delivery is vaginal in almost all
cases.
3.3.9 Transposition of the great arteries
Maternal risk
Though many women tolerate pregnancy relatively well, after an
atrial switch operation (Senning or Mustard repair) patients have
an increased risk of developing complications such as arrhythmias
(sometimes life-threatening), and heart failure (WHO risk class
III).93 Some of these women will have underlying bradycardia or
junctional rhythm. In these scenarios, b-blockers need to be
used cautiously, if at all. An irreversible decline in RV function
has been described in 10% of cases. Patients with more than mod-
erate impairment of RV function or severe TR should be advised
against pregnancy.
Obstetric and offspring risk
Pre-eclampsia and pregnancy-induced hypertension as well as off-
spring complications are more often encountered than in normal
pregnancy.
Management
Follow-up. It is recommended that patients with a Mustard or
Senning repair have monthly or bimonthly cardiac and echocardio-
graphic surveillance of symptoms, systemic RV function, and heart
rhythm.
Delivery. In asymptomatic patients with moderate or good ventricu-
lar function, vaginal delivery is advised. If ventricular function
deteriorates, an early caesarean delivery should be planned to
avoid the development or worsening of heart failure.113
Arterial switch operation
Only small series of patients with an arterial switch operation and
pregnancy have been described so far.114 The risk of pregnancy
seems low in these patients when there is a good clinical condition
pre-pregnancy. Vaginal delivery is advised.
3.3.10 Congenitally corrected transposition of the great
arteries
Maternal risk
In patients with congenitally corrected transposition of the great
arteries (also called atrioventricular and ventriculo-arterial
discordance), risk depends on functional status, ventricular func-
tion, presence of arrhythmias, and associated lesions. Patients
have an increased risk of developing complications such as arrhyth-
mias (sometimes life-threatening), and heart failure (WHO risk
class III). These patients are pre-disposed to developing AV
block; therefore, b-blockers must be used with extreme caution.
An irreversible decline in RV function has been described in 10%
of cases.115,116 Patients with NYHA functional class III or IV, impor-
tant ventricular dysfunction [ejection fraction (EF) ,40%], or
severe TR should be counselled against pregnancy.
Obstetric and offspring risk
The rate of fetal loss is increased.
Management
Follow-up. It is recommended that patients have frequent echo sur-
veillance of systemic RV function (every 4–8 weeks) and assess-
ment of symptoms and heart rhythm.
Delivery. In asymptomatic patients with moderate or good ventri-
cular function, vaginal delivery is advised. If ventricular function
deteriorates, an early caesarean delivery should be planned to
avoid the development or worsening of heart failure.
3.3.11 Fontan circulation
Maternal risk
Although successful pregnancy is possible in selected patients with
intensive monitoring, these are moderate to high risk pregnancies
and patients should be counselled carefully (WHO risk class III or
IV). There is probably a higher maternal risk if the Fontan circuit is
not optimal, and careful assessment pre-pregnancy is indicated.
Atrial arrhythmias and NYHA class deterioration have been
described.117,118 Patients with oxygen saturation ,85% at rest,
depressed ventricular function, and/or moderate to severe AV
regurgitation or with protein-losing enteropathy should be coun-
selled against pregnancy.
Obstetric and offspring risk
The offspring risk includes premature birth, small for gestational
age, and fetal death in up to 50%.
Management
Follow-up. It is recommended that Fontan patients have frequent
surveillance during pregnancy and the first weeks after delivery
(every 4 weeks), and care in a specialist unit is recommended.
Angiotensin-converting enzyme (ACE) inhibitors must be with-
drawn, and anticoagulant management is an issue. Even though
thrombo-embolic complications were not described in a literature
review on pregnancy in Fontan patients, the risk must be con-
sidered high and therapeutic anticoagulation should be con-
sidered.119 The thrombo-embolic risk may be lower in patients
treated with a total cavopulmonary Fontan correction.
Delivery. In principal, vaginal delivery is first choice. If ventricular
function deteriorates, an early caesarean delivery should be
planned in an experienced centre to avoid the development or
worsening of heart failure.
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3.4 Recommendations for the
management of congenital heart disease
4. Aortic diseases
Several heritable disorders affect the thoracic aorta, pre-disposing
patients to both aneurysm formation and aortic dissection. These
include the Marfan syndrome, bicuspid aortic valve, Ehlers–Danlos
syndrome, Turner syndrome, and familial forms of aortic dissec-
tion, aneurysm, or annuloaortic ectasia. Also other forms of con-
genital heart disease (e.g. tetralogy of Fallot, aortic coarctation)
may be accompanied by aortic dilatation or aneurysm formation,
and finally non-heritable aortic pathology may occur. Risk factors
for aortic pathology in the general population are hypertension
and advanced maternal age. Pregnancy is a high risk period for
all patients with aortic pathology, and aortic pathology is reported
as one of the leading causes of maternal mortality in the 2003–
2005 report of the UK Confidential Enquiry into Maternal And
Child Health.9 Recently, guidelines for the diagnosis and manage-
ment of patients with thoracic aortic disease have been
published.50
Diagnosis. A number of imaging procedures and genetic tests are
available, and are discussed in Sections 2.5 and 2.6.
4.1 Maternal and offspring risk
In addition to haemodynamic changes, hormonal changes occur
during pregnancy which lead to histological changes in the aorta,
increasing the susceptibility to dissection.120 Dissection occurs
most often in the last trimester of pregnancy (50%) or the early post-
partum period (33%). In all women with known aortic disease and/or
an enlarged aortic root diameter, the risks of pregnancy should be
discussed before conception. Women with previous aortic dissec-
tion are at high risk of aortic complications during pregnancy. Unfor-
tunately, not all patients with aortic pathology are aware that they
are at risk. Therefore, all women with genetically proven Marfan syn-
drome or other familial aortic pathology should have counselling on
the risk of dissection and the recurrence risk, and have a complete
evaluation including imaging of the entire aorta before pregnancy
(see Section 2.7). No irreversible effect of pregnancy on aortic dila-
tation has been proven.121 The diagnosis of aortic dissection should
be considered in all patients with chest pain during pregnancy as this
diagnosis is often missed.
4.2 Specific syndromes
4.2.1 Marfan syndrome
Patients with Marfan syndrome122,123 and a normal aortic root
diameter have a 1% risk of aortic dissection or other serious
Table 10 Recommendations for the management of
congenital heart disease
Recommendations Classa Level b
Pre-pregnancy relief of stenosis (usually by 
balloon valvulotomy) should be performed 
in severe pulmonary valve stenosis (peak 
Doppler gradient >64 mmHg). 
I B 68,105
Individual follow-up schedules should be 
arranged; ranging from twice during pregnancy 
to monthly.
I C
Symptomatic patients with Ebstein’s anomaly 
with cyanosis and/or heart failure should be 
treated before pregnancy or advised against 
pregnancy.
I C
In symptomatic women with marked dilatation 
of the right ventricle due to severe pulmonary 
regurgitation, pre-pregnancy pulmonary 
valve replacement (bioprosthesis) should be 
performed. 
I C
In asymptomatic women with a severely dilated 
right ventricle due to severe pulmonary 
regurgitation, pre-pregnancy pulmonary 
valve replacement (bioprosthesis) should be 
considered. 
IIa C
All women with a bicuspid aortic valve should 
undergo imaging of the ascending aorta before 
pregnancy, and surgery should be considered 




Recommendations Classa Level b
Anticoagulation treatment should be 
considered during pregnancy in Fontan 
patients.
IIa C
In PAH, associated anticoagulant treatment 
should be considered in patients with suspicion
of pulmonary embolism as the cause (or partly
the cause) of the pulmonary hypertension. 
IIa C
In patients who are already taking drug 
therapy for PAH before becoming pregnant, 
continuation should be considered after 
information about the teratogenic effects. 
IIa C
Women with pulmonary hypertension should 
be advised against pregnancy.c 
III C
Women with an oxygen saturation below 85% 
at rest should be advised against pregnancy. 
III C
Patients with TGA and a systemic right 
ventricle with more than moderate impairment 
of RV function and/or severe TR should be 
advised against pregnancy. 
III C
Fontan patients with depressed ventricular 
function and/or moderate to severe 
atrioventricular valvular regurgitation or with 
cyanosis or with protein-losing enteropathy 




cSee the text for detailed description and exceptions.
PAH ¼ pulmonary arterial hypertension; RV ¼ right ventricular; TGA ¼
complete transposition of the great arteries; TR ¼ tricuspid regurgitation.
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cardiac complication during pregnancy.124 In pregnant women with
Marfan syndrome, an aortic root diameter .4 cm and an increase
in aortic root diameter during pregnancy are risk factors for dissec-
tion.109,125 Although data about pregnancy in women with Marfan
syndrome and aortic root diameters .45 mm are scarce, preg-
nancy should be discouraged in these patients. Dissection is rare
with an aortic diameter ,40 mm, although a completely safe diam-
eter does not exist.126 With an aortic diameter of 40–45 mm, risk
factors for dissection (family history of dissection, rapid growth)
should be taken into account.121 Consideration of body surface
area is important, especially in women of small stature. Following
elective aortic root replacement, patients remain at risk for dissec-
tion in the residual aorta.127
In addition to life-threatening aortic dissection in these patients,
an increase in mitral regurgitation may occur and may lead to com-
plications such as supraventricular arrhythmias or heart failure,
especially in those patients who already had moderate to severe
regurgitation before pregnancy (see also Section 5 on valvular
disease).
4.2.2 Bicuspid aortic valve
Approximately 50% of the patients with a bicuspid aortic valve and
AS have dilatation of the ascending aorta.128 Dilatation is often
maximal in the distal part of the ascending aorta, which cannot
be adequately visualized echocardiographically; therefore, MRI or
CT should be performed pre-pregnancy. Dissection does occur,
although less frequently than in Marfan patients.109 The risk of
pregnancy in women with bicuspid aortic valve and dilated aorta
has not been systematically investigated. In patients with an
aortic root .50 mm, pre-pregnancy surgery should be
considered.19
4.2.3 Ehlers–Danlos syndrome
Aortic involvement occurs almost exclusively in Ehlers–Danlos
syndrome type IV which is transmitted as an autosomal dominant
trait. During pregnancy women may show increased bruising,
hernias, and varicosities, and suffer rupture of large vessels or
rupture of the uterus. Because of the risk of uterine rupture,
Ehlers–Danlos syndrome type IV is a contraindication for preg-
nancy. Aortic dissection may occur without dilatation. The role
of prophylactic surgery is less well established in this patient
group because the risk–benefit ratio is influenced by the fact
that surgical repair may be complicated by tissue fragility, ten-
dency to haemorrhage extensively, and poor wound
healing.129,130
4.2.4 Turner syndrome
The prevalence of cardiovascular malformations in Turner syn-
drome is 25–50% and hypertension is also often present. Although
no quantitative evidence exists on the risk of dissection attribu-
table to pregnancy in women with Turner syndrome, the risk
probably is increased and is higher if the woman has additional
risk factors such as bicuspid aortic valve, CoA, and/or hyperten-
sion.131 Women at highest risk are those with aortic dilatation,
but dissection may also occur in the absence of any dilatation.
Thoracic aortic diameters must be evaluated in relation to body
surface area as these patients often have short stature. An aortic
diameter index .27 mm/m2 is associated with a high risk of dissec-
tion, and prophylactic surgery should be considered. Aortic com-
plications during pregnancy are associated with maternal
mortality of up to 11%, mainly attributable to type A dissection.
The risk of (pre)eclampsia is increased, and treatment of hyperten-
sion is important, especially during pregnancy.
4.3 Management
Follow-up and medical therapy. Depending on the aortic diameter,
patients with aortic pathology should be monitored by echocardio-
graphy at 4–12 week intervals throughout the pregnancy and 6
months post-partum. Pregnancy should be supervised by a cardiol-
ogist and obstetrician who are alert to the possible complications.
Treatment with b-blocking agents may reduce the rate of aortic
dilatation and might improve survival. However, in a recent
meta-analysis,132 including mostly studies with non-pregnant
patients, a beneficial effect was not confirmed. In spite of these
uncertainties, the Task Force recommends the use of b-blockers
in patients with Marfan syndrome during pregnancy to prevent dis-
section. In patients with Ehlers–Danlos syndrome type IV, celipro-
lol is recommended because of the very high risk of dissections and
the benefit demonstrated in non-pregnant patients.130 Fetal growth
should be monitored when the mother is taking b-blockers.
Interventions. In patients with Marfan syndrome or other syndromes
with high risk of dissection, such as Loeys–Dietz syndrome,
Ehlers–Danlos, or Smad-3 gen mutation,133 pre-pregnancy
surgery is recommended when the ascending aorta is ≥45 mm,
depending on individual characteristics. In other patients with dila-
tation of the aorta, pre-pregnancy surgery should be considered
when the ascending aorta is ≥50 mm. Body surface area should
probably be taken into account in small women. An aortic diam-
eter index .27 mm/m2 is associated with a high risk of dissection,
and prophylactic surgery should be considered. When progressive
dilatation occurs during pregnancy, before the fetus is viable, aortic
repair with the fetus in utero should be considered. When the fetus
is viable, caesarean delivery followed directly by aortic surgery is
recommended (see Section 2.8.2). Caesarean section should be
performed in a hospital in which cardiothoracic surgery and neo-
natal intensive care facilities are available. Ascending aortic dissec-
tion occurring during pregnancy is a surgical emergency; senior
cardiothoracic, cardiology, obstetric, and anaesthetic physicians
must act rapidly to deliver the fetus (if viable) by caesarean delivery
in cardiac theatres and proceed directly to repair of the dissection.
Delivery (see also Section 2.9). The primary aim of intrapartum man-
agement in patients with ascending aorta enlargement is to reduce
the cardiovascular stress of labour and delivery. If the woman is
taking b-blockers during pregnancy they should be continued in
the peripartum period. If the ascending aorta diameter is 40–
45 mm, vaginal delivery with expedited second stage and regional
anaesthesia is advised to prevent BP peaks, which may induce dis-
section. Caesarean delivery may also be considered in these
patients, based on the individual situation. Regional anaesthesia
techniques can be difficult in Marfan patients, depending on the
presence and severity of scoliosis and presence of dural
ectasia.134 Caesarean delivery should be considered when the
aortic diameter exceeds 45 mm. It is advised to perform early
caesarean delivery for women with Ehlers–Danlos syndrome
type IV.
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4.4 Recommendations for the
management of aortic disease
5. Valvular heart disease
Both acquired and congenital valvular heart diseases are important
causes of maternal and fetal morbidity and mortality. Rheumatic
heart disease remains a major problem in developing countries
and is still seen in western countries, especially in immigrants. Ste-
notic valve diseases carry a higher pregnancy risk than regurgitant
lesions, and left-sided valve diseases have a higher complication
rate than right-sided valve lesions.12,56,57,135 Specific problems,
mainly related to anticoagulant therapy, are present in women
with mechanical valve prostheses.
5.1 Stenotic valve lesions
In stenotic valve diseases, increased CO causes an increase in
transvalvular gradient and, thus, upstream pressures, and there is
an increased risk of maternal and fetal complications.12,102
5.1.1 Mitral stenosis
Moderate or severe mitral stenosis (MS) is poorly tolerated during
pregnancy. MS is responsible for most of the morbidity and mor-
tality of rheumatic heart disease during pregnancy. The diagnosis
is based on echocardiography.7,136 Pressure half-time is less reliable
than direct planimetry but can be used during pregnancy.136 Gra-
dient and PAP do not directly reflect the severity of MS during
pregnancy but have an important prognostic value.136 The assess-
ment of mitral anatomy and the quantitation of associated regurgi-
tation or other valvular diseases are particularly important when
percutaneous mitral commissurotomy is considered.7,136 Exercise
testing is useful to reveal symptoms and assess exercise tolerance.
Maternal risk
The risk of decompensation depends on the severity of MS.102,137
Heart failure occurs frequently in pregnant women with moderate
or severe MS (valve area ,1.5 cm2), particularly during the second
and third trimesters, even in previously asymptomatic
women.102,135,137 Heart failure is often progressive. Pulmonary
oedema may occur, particularly when MS is unknown or if AF
occurs. AF, although rare (,15%), carries the additional risk of
thrombo-embolic events.102,137 Mortality is between 0 and
3%.102,135,137 Symptoms may be precipitated in women with mild
MS, but they are generally not severe and are well tolerated.102,135
Obstetric and offspring risk
Obstetric complications are mainly related to the risk of acute
heart failure during or just after delivery, and they depend on
symptoms and PAP during pregnancy.135 Prematurity rates are
20–30%, intrauterine growth retardation 5–20%, and stillbirth
1–3%.102,137 Offspring risk is higher in women in NYHA class III/
IV during pregnancy.12,135
Management
All patients with moderate or severe MS (even when asympto-
matic) should be counselled against pregnancy and intervention
should be performed pre-pregnancy, favouring percutaneous
interventions.7
Follow-up. Clinical and echocardiographic follow-up is indicated
monthly or bimonthly depending on haemodynamic tolerance. In
mild MS, evaluation is recommended every trimester and prior
to delivery.
Table 11 Recommendations for the management of
aortic disease
Recommendations Classa Levelb
Women with Marfan syndrome or other known 
aortic disease should be counselled about the 
risk of aortic dissection during pregnancy and 
the recurrence risk for the offspring. 
I C
Imaging of the entire aorta (CT/MRI) should 
be performed before pregnancy in patients 
with Marfan syndrome or other known aortic 
disease.
I C
Women with Marfan syndrome and an 
ascending aorta >45 mm should be treated 
surgically pre-pregnancy.
I C
In pregnant women with known aortic 
dilatation, (history of) type B dissection or 
genetic predisposition for dissection strict blood 
pressure control is recommended.
I C
Repeated echocardiographic imaging every 4–8 
weeks should be performed during pregnancy in 
patients with ascending aorta dilatation.
I C
For imaging of pregnant women with dilatation 
of the distal ascending aorta, aortic arch or 
descending aorta, MRI (without gadolinium) is 
recommended. 
I C
In women with a bicuspid aortic valve imaging of 
the ascending aorta is recommended. 
I C
In patients with an ascending aorta <40 mm,
vaginal delivery is favoured.
I C
Women with aortic dilatation or (history of) 
aortic dissection should deliver in a centre 
where cardiothoracic surgery is available.
I C
In patients with an ascending aorta >45 mm,
caesarean delivery should be considered.
I C
Surgical treatment pre-pregnancy should be 
considered in women with aortic disease 
associated with a bicuspid aortic valve 
when the aortic diameter is >50mm 
(or >27 mm/m2 BSA).
IIa C
Prophylactic surgery should be considered 
during pregnancy if the aortic diameter 
is ≥50 mm and increasing rapidly.
IIa C
In Marfan, and other patients with an aorta 
40–45 mm, vaginal delivery with epidural 
anaesthesia and expedited second stage should 
be considered.
IIa C
In Marfan, and other patients with an aorta 
40–45 mm, caesarean section may be considered.
IIb C
Patients with (or history of) type B dissection 




CT ¼ computed tomography; MRI ¼ magnetic resonance imaging.
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Medical therapy. When symptoms or pulmonary hypertension
(echocardiographically estimated systolic PAP .50 mmHg)
develop, activity should be restricted and b1-selective blockers
commenced.7,64 Diuretics may be used if symptoms persist, avoid-
ing high doses.64 Therapeutic anticoagulation is recommended in
the case of paroxysmal or permanent AF, left atrial thrombosis,
or prior embolism.7,64 It should also be considered in women
with moderate or severe MS and spontaneous echocardiographic
contrast in the left atrium, large left atrium (≥40 mL/m2), low
CO, or congestive heart failure, because these women are at
very high thrombo-embolic risk.
Interventions during pregnancy. Percutaneous mitral commissurot-
omy is preferably performed after 20 weeks gestation. It should
only be considered in women with NYHA class III/IV and/or esti-
mated systolic PAP .50 mmHg at echocardiography despite
optimal medical treatment, in the absence of contraindications
and if patient characteristics are suitable.7,64 It should be per-
formed by an experienced operator, and in experienced hands
has a low complication rate. Abdominal lead shielding is rec-
ommended.7,64 The radiation dose should be minimized by
keeping screening time as short as possible.7,64 Given the risk of
complications, percutaneous mitral commissurotomy should not
be performed in asymptomatic patients. Closed commissurotomy
remains an alternative in developing countries when percutaneous
commissurotomy is not available. Open-heart surgery should be
reserved for cases in which all other measures fail and the
mother’s life is threatened.
Delivery. Vaginal delivery should be considered in patients with mild
MS, and in patients with moderate or severe MS in NYHA class I/II
without pulmonary hypertension. Caesarean section is considered
in patients with moderate or severe MS who are in NYHA class III/
IV or have pulmonary hypertension despite medical therapy, in
whom percutaneous mitral commissurotomy cannot be per-
formed or has failed.
5.1.2 Valvular aortic stenosis
In women of childbearing age the main cause of AS is congenital
bicuspid aortic valve. Patients can be asymptomatic, even with
severe AS.7 Symptoms may first occur during pregnancy. Echocar-
diography is mandatory for the diagnosis.7,136 Exercise testing is
recommended in asymptomatic patients before pregnancy to
confirm asymptomatic status and evaluate exercise tolerance, BP
response, arrhythmias, and/or the need for interventions. In
women with bicuspid aortic valve, aortic diameters should be
assessed before and during pregnancy.
Maternal risk
Cardiac morbidity during pregnancy is related to severity of AS and
symptoms. With asymptomatic mild or moderate AS, pregnancy is
well tolerated. Also patients with severe AS may sustain pregnancy
well, as long as they remain asymptomatic during exercise testing
and have a normal BP response during exercise.19,139
The increase in CO can lead to a marked increase in gradi-
ent.135,139 Heart failure occurs in 10% of patients with severe
AS and arrhythmias in 3–25%.140 Mortality is now rare if careful
management is provided. 8,56,74,102,135,139,140 Women with bicuspid
aortic valve have a risk of aortic dilatation and dissection (see
Section 4.3.2).
Obstetric and offspring risk
Obstetric complications may be increased in patients with severe
AS (hypertension-related disorders in 13%, premature labour).140
Pre-term birth, intrauterine growth retardation, and low birth
weight occur in up to 25% of the offspring of mothers with mod-
erate and severe AS.
Management
All symptomatic patients with severe AS or asymptomatic patients
with impaired LV function or a pathological exercise test should be
counselled against pregnancy, and valvuloplasty or surgery should
be performed pre-pregnancy, according to guidelines.7,19 Preg-
nancy needs not be discouraged in asymptomatic patients, even
with severe AS, when LV size and function as well as the exercise
test are normal and severe LV hypertrophy (posterior wall
.15 mm) has been excluded. There should also be no evidence
of recent progression of AS.74,139,140,141 Regardless of symptoms,
pre-pregnancy surgery should be considered in patients with an
ascending aorta .50 mm (27.5 mm/m2).
Follow-up. Regular follow-up during pregnancy is required by an
experienced team. In severe AS, monthly or bimonthly cardiac
evaluations including echocardiography are advised to determine
symptom status, progression of AS, or other complications.
Medical therapy. Medical treatment and restricted activities are indi-
cated for patients developing signs or symptoms of heart failure
during pregnancy. Diuretics can be administered for congestive
symptoms. A b-blocker or a non-dihydropyridine calcium
channel antagonist should be considered for rate control in AF.
If both are contraindicated, digoxin may be considered.142
Interventions during pregnancy. During pregnancy in severely sympto-
matic patients not responding to medical therapy, percutaneous
valvuloplasty can be undertaken in non-calcified valves with
minimal regurgitation.143 If this is not possible and patients have
life-threatening symptoms, valve replacement should be con-
sidered after early delivery by caesarean section if this is an
option (see Section 2.7.2).
Delivery. In severe AS, particularly with symptoms during the
second half of the pregnancy, caesarean delivery should be pre-
ferred with endotracheal intubation and general anaesthesia. In
non-severe AS, vaginal delivery is favoured, avoiding a decrease
in peripheral vascular resistance during regional anaesthesia and
analgesia.
5.2 Regurgitant lesions
5.2.1 Mitral and aortic regurgitation
Mitral and aortic regurgitation at childbearing age can be of rheu-
matic, congenital, or degenerative origin. Previous valvulotomy and
infective endocarditis can be associated factors. A rare cause of
acute valvular regurgitation during pregnancy is antiphospholipid
syndrome. Left-sided regurgitant valve lesions carry a lower preg-
nancy risk than stenotic valve lesions because the decreased sys-
temic vascular resistance reduces regurgitant volume. Severe
regurgitation with LV dysfunction is poorly tolerated, as is acute
severe regurgitation. Evaluation is preferably performed pre-
conception, and should include assessment of symptoms, echocar-
diographic evaluation of regurgitation severity (integrative approach
according to ESC criteria), and LV dimensions and function.7 In mod-
erate/severe regurgitation, exercise testing is recommended pre-
pregnancy. Ascending aortic diameters should be measured in
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women with aortic regurgitation, especially in those with bicuspid
valves.
Maternal risk
Maternal cardiovascular risk depends on regurgitation severity,
symptoms, and LV function.135 Women with severe regurgitation
and symptoms or compromised LV function are at high risk of
heart failure.135 In asymptomatic women with preserved LV function
the most frequent complications are arrhythmias. In women with
congenital heart disease, significant left AV valve regurgitation has
been reported to be associated with cardiac complications during
pregnancy. This association may be partly attributable to ventricular
dysfunction. A persistent worsening of regurgitation may occur.57,99
Obstetric and offspring risk
No increased risk of obstetric complications has been reported. In
symptomatic regurgitation the risk of offspring complications is
increased.12
Management
Patients with severe regurgitation and symptoms or compromised
LV function or LV dilatation (according to criteria of guidelines for
valvular heart disease)7 should be referred for pre-pregnancy
surgery favouring valve repair.
Follow-up. Follow-up is required every trimester in mild/moderate
regurgitation, and more often in severe regurgitation. Follow-up
plans need to be individualized according to clinical status and
symptoms.
Medical therapy and intervention during pregnancy. Symptoms of fluid
overload can usually be managed medically. In acute severe regur-
gitation with therapy-refractory heart failure, surgery is sometimes
unavoidable during pregnancy. If the fetus is sufficiently mature,
delivery should be undertaken prior to cardiac surgery (see
Section 2.8.2).
Delivery. Vaginal delivery is preferable; in symptomatic patients
epidural anaesthesia and shortened second stage is advisable.
5.2.2 Tricuspid regurgitation
TR is usually functional (annular dilatation due to RV pressure or
volume overload); alternatively, endocarditis or Ebstein’s anomaly
can be the cause. The diagnostic work-up consists of clinical and
echocardiographic assessment.7 Maternal cardiovascular risk is
usually determined by primary left-sided valve disease or pulmonary
hypertension. However, maternal risk can be increased in severe
symptomatic TR or in women with RV dysfunction.76 In women
with congenital heart disease, moderate/severe tricuspid AV valve
regurgitation may be associated with maternal cardiac complications
(possibly dependent on ventricular function), mainly arrhythmias.57
Even severe TR with heart failure can usually be managed con-
servatively during pregnancy (Table 12). When surgery is necessary
for left-sided valve lesions before or during pregnancy, additional
tricuspid repair is indicated in severe TR and should be considered
in moderate TR and moderate secondary TR with annular dilata-
tion (.40 mm).7 In severe symptomatic TR, repair should be con-
sidered pre-pregnancy. The preferred mode of delivery is vaginal in
almost all cases.
5.3 Valvular atrial fibrillation (native
valves)
A high thrombo-embolic risk is associated with valvular AF. This is
particularly pronounced in patients with severe MS. With the
occurrence of AF, immediate anticoagulation with i.v. UFH is
required, followed by LMWH in the first and last trimester and
OACs or LMWH for the second trimester. LMWH should be
given in weight-adjusted therapeutic doses (twice daily) until 36 h
prior to delivery. If OACs are used, the INR can be kept
between 2.0 and 2.5, thus minimizing the risk for the fetus.
5.4 Prosthetic valves
5.4.1 Choice of valve prosthesis
When implantation of a prosthetic valve is unavoidable in a woman
who desires to become pregnant in the future, the valve selection
is problematic.
Mechanical valves offer excellent haemodynamic performance
and long-term durability, but the need for anticoagulation increases
fetal and maternal mortality and morbidity. Bioprosthetic valves
also offer good haemodynamic performance and are much less
thrombogenic. Their use in young women, however, is associated
with a high risk of structural valve deterioration, occurring in
50% of women ,30 years of age at 10 years post-implantation,
and is greater in the mitral position than in the aortic and tricuspid
position. In the pulmonary position, transcatheter valve implan-
tation is an option in an increasing number of patients, particularly
after previous bioprosthesis implantation. There is conflicting evi-
dence as to whether or not pregnancy accelerates bioprosthetic
degeneration.144 However, young patients with a biological valve
will almost certainly need a reoperation, with a mortality risk of
0–5%, depending on valve position and degree of emergency.
In patients with aortic valve disease, the Ross operation (pul-
monary autograft transferred to the aortic position and pulmonary
valve replacement with a homograft) can be an alternative. There is
no risk of valve thrombosis, and valve haemodynamics are excel-
lent. Yet this is a two-valve operation requiring specific surgical
expertise, and with a significant reoperation rate after 10 years.
Moreover, only few data are available about pregnancy in
women after a Ross procedure.145 A desire for pregnancy is con-
sidered a class IIb indication for a biological valve.7 The choice for a
specific prosthesis should be made after extensive patient infor-
mation and discussion with the patient.
5.4.2 Bioprosthesis
Pregnancy is generally well tolerated in women with a bioprosthetic
valve. Maternal cardiovascular risk is mainly dependent on bio-
prosthesis function. The risk is low in women with no or minimal bio-
prosthesis dysfunction and uncompromised ventricular function.144
Pre-pregnancy assessment and counselling as well as follow-up,
medical treatment, and indications for intervention are comparable
with those for pregnancies with native valve dysfunction.
5.5 Mechanical prosthesis and
anticoagulation
Haemodynamically, women with well-functioning mechanical
valves tolerate pregnancy well. Yet the need for anticoagulation
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raises specific concerns because of an increased risk of valve
thrombosis, of haemorrhagic complications, and of offspring com-
plications. Pregnancy is associated with increased maternal risk.
The character and magnitude of the risk depend on the anticoagu-
lation regimen used during pregnancy and the quality of anticoagu-
lation control. Pre-pregnancy evaluation should include assessment
of symptoms and echocardiographic evaluation of ventricular func-
tion, and prosthetic and native valve function.
Maternal risk
Mechanical valves carry the risk of valve thrombosis which is
increased during pregnancy. In a large review, this risk was 3.9%
with OACs throughout pregnancy, 9.2% when UFH was used in
the first trimester and OACs in the second and third trimester,
and 33% with UFH throughout pregnancy.146 Maternal death
occurred in these groups in 2, 4, and 15%, respectively, and was
usually related to valve thrombosis.146 A review of the recent lit-
erature confirmed the low risk of valve thrombosis with OACs
throughout pregnancy (2.4%, 7/287 pregnancies) compared with
UFH in the first trimester (10.3%, 16/156 pregnancies).147 The
risk is probably lower with adequate dosing and is also dependent
on the type and position of the mechanical valve, as well as on
additional patient-related risk factors.7 UFH throughout pregnancy
is additionally associated with thrombocytopenia and osteoporosis.
LMWHs are also associated with the risk of valve thrombo-
sis.148,149 The risk is lower, but still present, with dose adjusting
according to anti-Xa levels.147,148,150 – 152 In 111 pregnancies in
which LMWH with dose adjustment according to anti-Xa levels
was used throughout pregnancy, valve thrombosis occurred in
9%.147,150 –152 Too low target anti-Xa levels or poor compliance
probably contributed to valve thrombosis in all but one pregnancy.
A review reported lower frequency of valve thrombosis with
LMWH in the first trimester only, but in a small patient group
(3.6%, 2/56 pregnancies).147
The use of LMWH during pregnancy in women with mechanical
prostheses is still controversial because evidence is scarce. Unre-
solved questions concern optimal anti-Xa levels, the importance
of peak vs. pre-dose levels, and the best time intervals for
anti-Xa monitoring. Studies are urgently needed.
There is a marked increase in dose requirement during preg-
nancy to keep the anti-Xa levels in the therapeutic range,151,153
because of increased volume of distribution and increased renal
clearance. Therefore, regular monitoring of anti-Xa levels is
necessary. It has been demonstrated that pre-dose anti-Xa levels
are often subtherapeutic when peak levels are between 0.8 and
1.2 U/mL.153,154 Even when pre-dose anti-Xa level monitoring
and more frequent dosing lead to higher pre-dose levels combined
with lower peak levels, there are no data available to show that this
approach achieves a stable, consistent therapeutic intensity of
anticoagulation and will prevent valve thrombosis and
bleeding.152 –154
Current evidence indicates that OACs throughout pregnancy,
under strict INR control, is the safest regimen for the
mother.146,147,155 However, adequate randomized studies that
compare different regimens are not available. The superiority of
either UFH or LMWH in the first trimester is unproven, though
a recent review suggests higher efficacy of LMWH.147 No
LMWH is officially approved (labelled) for pregnant women with
mechanical valves.
Obstetric and offspring risk. All anticoagulation regimens carry an
increased risk of miscarriage and of haemorrhagic complications,
including retroplacental bleeding leading to premature birth and
fetal death.144,146,148,150 –152 Comparison between studies is ham-
pered, however, by reporting differences. OACs cross the placenta
and their use in the first trimester can result in embryopathy in
0.6–10% of cases.146,156 –158 UFH and LMWH do not cross the
placenta and embryopathy does not occur. Substitution of OACs
with UFH in weeks 6–12 greatly decreases the risk. The incidence
of embryopathy was low (2.6%) in a small series when the warfarin
dose was ,5 mg and 8% when the warfarin dose was .5 mg
daily.159 The dose dependency was confirmed in a recent
series.155 Major central nervous system abnormalities occur in
1% of children when OACs are used in the first trimester.158
A low risk of minor central nervous system abnormalities exists
with OACs outside the first trimester only.158 Vaginal delivery
while the mother is on OACs is contraindicated because of the
risk of fetal intracranial bleeding.
Management
Valve and ventricular dysfunction should be considered, and the
type and position of valve(s) as well as the history of valve throm-
bosis should be taken into account. The advantages and disadvan-
tages of different anticoagulation regimens should be discussed
extensively. The mother and her partner must understand that
according to current evidence use of OACs is the most effective
regimen to prevent valve thrombosis, and therefore is the safest
regimen for her, and risks for the mother also jeopardize the
baby. On the other hand the risk of embryopathy and fetal haem-
orrhage needs to be discussed, considering OAC dose. Compli-
ance with prior anticoagulant therapy should be considered. The
management of the regimen that is chosen should be planned in
detail.
Follow-up. The effectiveness of the anticoagulation regimen should
be monitored weekly and clinical follow-up including echocardio-
graphy should be performed monthly.
Medical therapy. The main goal of anticoagulation therapy in these
women is to prevent the occurrence of valve thrombosis and its
lethal consequences for both mother and fetus. The following rec-
ommendations should be seen in this perspective. OACs should be
continued until pregnancy is achieved. UFH or LMWH throughout
pregnancy is not recommended because of the high risk of valve
thrombosis with these regimens in combination with low fetal
risk with OACs in the second and third trimester. Continuation
of OACs throughout pregnancy should be considered when the
warfarin dose is ,5 mg daily (or phenprocoumon ,3 mg or ace-
nocoumarol ,2 mg daily) because the risk of embryopathy is low,
while OACs are in large series the most effective regimen to
prevent valve thrombosis.146,147 After the mother has been given
full information that OACs throughout pregnancy is by far the
safest regimen for her and the risk for embryopathy is ,3%, dis-
continuation of OACs and a switch to UFH or LMWH between
weeks 6 and 12 under strict dose control and supervision (as indi-
cated below) may be considered after discussion on an individual
basis in patients with a low dose requirement. When a higher
dose of OACs is required, discontinuation of OACs between
weeks 6 and 12 and replacement by adjusted-dose UFH (aPTT
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≥2 times the control, in high risk patients applied as an i.v. fusion)
or LMWH twice daily with dose adjustment according to weight
and according to anti-Xa levels (Table 12) should be considered.
The anti-Xa level should be maintained between 0.8 and 1.2 U/
mL, determined 4–6 h after application (Table 12).4,7 The Task
Force advises weekly control of peak anti-Xa levels because of
the need for increasing dosages of LMWH during preg-
nancy.2,4,7,147,151,153 As an alternative, continuation of OACs may
be considered in these patients after fully informed consent.
The importance of also monitoring the pre-dose level of anti-Xa,
and the need to maintain this level above 0.6 IU/mL, has not been
studied sufficiently, particularly in relation to thrombo-embolic
events and bleeding, to make firm recommendations. The starting
dose for LMWH is 1 mg/kg body weight if enoxaparin is chosen
and 100 IU/kg for dalteparin, given twice daily subcutaneously.
The dose should be adjusted according to increasing weight
during pregnancy160 and anti-Xa levels. The Task Force does not
recommend the addition of acetylsalicylic acid to this regimen
because there are no data to prove its efficacy and safety in preg-
nant women. The use of LMWH in the first trimester is limited by
the scarceness of data about its efficacy147 and safety, uncertainties
concerning optimal dosing to prevent both valve thrombosis and
bleeding, and variable availability of anti-Xa level testing.
Irrespective of the regimen used, the effect of the anticoagulants
should be monitored very carefully, and in the case of OACs the
INR should be determined at weekly intervals. The intensity of
the INR should be chosen according to the type and location of
the prosthetic valve, according to present guidelines.4,7 Intense
education about anticoagulation and self-monitoring of anticoagu-
lation in suitable patients is recommended. In case UFH is used
it should, when a stable aPTT has been achieved, be monitored
weekly by the aPTT, 4–6 h after starting the first dose, with a pro-
longation of ≥2 times the control.
Diagnosis and management of valve thrombosis. When a woman with
a mechanical valve presents with dyspnoea and/or an embolic
event, immediate transthoracic echocardiography is indicated to
search for valve thrombosis, usually followed by transoesophageal
echocardiography. If necessary, fluoroscopy can be performed
with limited fetal risk. Management of valve thrombosis is compar-
able with management in non-pregnant patients. This includes opti-
mizing anticoagulation with i.v. heparin and resumption of oral
anticoagulation in non-critically ill patients with recent subthera-
peutic anticoagulation, and surgery when anticoagulation fails and
for critically ill patients with obstructive thrombosis.7 Most fibrino-
lytic agents do not cross the placenta, but the risk of embolization
(10%) and of subplacental bleeding is a concern, and experience in
pregnancy is limited. Fibrinolysis should be applied in critically ill
patients when surgery is not immediately available. Because fetal
loss is high with surgery, fibrinolysis may be considered instead
of surgery in non-critically ill patients when anticoagulation fails.
Fibrinolysis is the therapy of choice in right-sided prosthetic
valve thrombosis.7 The mother should be informed about the risks.
Delivery (see also Section 2.9). Planned vaginal delivery is usually
preferred, with prior switch to heparin. A planned caesarean
section may be considered as an alternative, especially in patients
with a high risk of valve thrombosis, in order to keep the time
without OACs as short as possible. Caesarean delivery should be
performed if labour onset occurs while the patient is still on OACs.
5.6 Recommendations for the
management of valvular heart disease
Table 12 Recommendations for the management of valvular heart disease
Recommendations Classa Level b
Mitral stenosis
In patients with symptoms or pulmonary hypertension, restricted activities and β1-selective blockers are recommended. I B 7,64
Diuretics are recommended when congestive symptoms persist despite β-blockers. I B 64
Patients with severe MS should undergo intervention before pregnancy. I C
Therapeutic anticoagulation is recommended in the case of atrial fibrillation, left atrial thrombosis, or prior embolism. I C
Percutaneous mitral commissurotomy should be considered in pregnant patients with severe symptoms or systolic pulmonary 
artery pressure >50 mmHg despite medical therapy.
IIa C
Aortic stenosis
Patients with severe AS should undergo intervention pre-pregnancy if:
 • they are symptomatic I B 7
 • or LV dysfunction ( LVEF <50%) is present I C
Asymptomatic patients with severe AS should undergo intervention pre-pregnancy when they develop symptoms during exercise 
testing.
I C
Asymptomatic patients with severe AS should be considered for intervention pre-pregnancy when a fall in blood pressure below 
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6. Coronary artery disease and
acute coronary syndromes
The diagnostic criteria of acute coronary syndrome (ACS) during
pregnancy or in the puerperium are similar to those for non-
pregnant patients and consist of chest pain, ECG changes, and
cardiac biomarkers. However, negative T waves may appear at
an increased rate in pregnancy in non-ischaemic conditions. An
increase in the level of troponin I should lead the investigating
physician to consider the diagnosis of underlying ischaemic heart
disease, even if pre-eclampsia is present.161 Timely diagnosis is
often delayed, as presenting symptoms may be attributed to preg-
nancy. The main differential diagnoses of acute ischaemic chest
pain are pre-eclampsia, acute pulmonary embolism, and aortic dis-
section. Echocardiography can be safely used to evaluate the pres-
ence of wall motion abnormalities. Exercise ECG or exercise
echocardiography can be performed in stable patients, whereas
radionuclide stress tests should be avoided because of radiation.
Severe post-partum haemorrhage with haemorrhagic shock may
also lead to elevated troponin levels with ischaemic ECG
changes and LV wall motion abnormalities.
6.1 Maternal and offspring risk
With the rise in maternal age and the increasing number of high
risk women who become pregnant, pregnancy-related ACS are
expected to increase. Pregnancy may be considered in women
with known coronary artery disease in the absence of residual
ischaemia and clinical signs of LV dysfunction. Cardiac risk assess-
ment before conception is highly recommended (see Section
2.11). During pregnancy an ACS is rare and estimated at 3–6
per 100 000 deliveries.162 – 164 It is strongly related to the major




Patients with severe aortic or mitral regurgitation and symptoms or impaired ventricular function or ventricular dilatation should be 
treated surgically pre-pregnancy.
I C
Medical therapy is recommended in pregnant women with regurgitant lesions when symptoms occur. I C
OACs are recommended during the second and third trimesters until the 36th week. I C
Change of anticoagulation regimen during pregnancy should be implemented in hospital. I C
If delivery starts while on OACs, caesarean delivery is indicated. I C
OAC should be discontinued and dose-adjusted UFH (a PTT ≥2× control) or adjusted-dose LMWH (target anti-Xa level 4–6 hours 
post-dose 0.8-1.2 U/mL) started at the 36th week of gestation. 
I C
In pregnant women managed with LMWH, the post-dose anti-Xa level should be assessed weekly. I C
LMWH should be replaced by intravenous UFH at least 36 hours before planned delivery. UFH should be continued until 4–6 hours 
before planned delivery and restarted 4–6 hours after delivery if there are no bleeding complications.
I C
Immediate echocardiography is indicated in women with mechanical valves presenting with dyspnoea and/or an embolic event. I C
Continuation of OACs should be considered during the first trimester if the warfarin dose required for therapeutic anticoagulation is
<5 mg/day (or phenprocoumon <3 mg/day or acenocoumarol <2 mg/day), after patient information and consent. 
IIa C
Discontinuation of OAC between weeks 6 and 12 and replacement by adjusted-dose UFH (a PTT ≥2× control; in high risk patients 
applied as intravenous infusion) or LMWH twice daily (with dose adjustment according to weight and target anti-Xa level 4–6 hours 
post-dose 0.8–1.2 U/mL) should be considered in patients with a warfarin dose required of >5 mg/day (or phenprocoumon 
>3 mg/day or acenocoumarol >2mg/day).
IIa C
Discontinuation of OACs between weeks 6 and 12  and replacement by UFH or LMWH under strict dose control (as described 
above) may be considered on an individual basis in patients with warfarin dose required for therapeutic anticoagulation <5 mg/day (or 
phenprocoumon <3 mg/day or acenocoumarol <2 mg/day).
IIb C
Continuation of OACs may be considered between weeks 6 and 12 in patients with a warfarin dose required for therapeutic 
anticoagulation >5 mg/day (or phenprocoumon >3 mg/day or acenocoumarol >2 mg/day).
IIb C
LMWH should be avoided, unless anti-Xa levels are monitored. III C
Recommendations Classa Level b
aClass of recommendation.
bLevel of evidence.
aPTT ¼ activated partial thromboplastin time; AS ¼ aortic stenosis; LMWH ¼ low molecular weight heparin; LVEF ¼ left ventricular ejection fraction; MS ¼ mitral stenosis;
OACs ¼ oral anticoagulants; UFH ¼ unfractionated heparin.
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hyperlipidaemia, older age, diabetes mellitus, and a positive family
history. Other conditions that contribute to ACS risk are (pre)e-
clampsia, thrombophilia, post-partum infections, and severe post-
partum haemorrhage.161,163– 165 Pregnancy-related ACS can
occur during all stages of gestation. Spontaneous coronary artery
dissections are more prevalent among pregnant than non-pregnant
women, and are mostly reported around delivery or in the early
post-partum period.163 They may be related to high progesterone
levels with subsequent structural changes in the collagen of the
vessel wall. Ergometrine given for bleeding post-partum may lead
to coronary vasospasm and ischaemia. Thrombi and dissections
occur more frequently in the peripartum period than before
delivery.163
Maternal mortality after ACS is estimated at 5–10% and is
highest during the peripartum period. Survival has improved with
primary percutaneous coronary intervention (PCI).162 – 164 Long-
term maternal prognosis mainly depends on infarct size and the
cardiovascular risk profile. Before delivery, ACS may result in
fetal mortality and prematurity, the risk of which is mainly
related to the severity of maternal heart disease.
6.2 Management
The first step in ST-elevation ACS is to refer the patient immedi-
ately to a skilled intervention centre for a diagnostic angiogram and
a primary PCI.
Interventions during pregnancy. Coronary angiography with the
possibility of coronary intervention (PCI) is preferred to throm-
bolysis as it will also diagnose coronary artery dissection. The
risk of potential damage to the fetus should be kept in mind,
especially in the first trimester. All reported stenting during
the acute phase of ST-elevation myocardial infarction during
pregnancy utilized bare metal stents; the safety of drug-eluting
stents in pregnant woman is therefore still unknown. As
drug-eluting stents also require prolonged dual antiplatelet
therapy they should be avoided. Although recombinant tissue
plasminogen activator does not cross the placenta it may
induce bleeding complications (subplacental bleeding); therefore,
thrombolytic therapy should be reserved for life-threatening
ACS when there is no access to PCI.166 In women with
non-ST elevation ACS with intermediate or high risk criteria,
an invasive approach to assess coronary anatomy is indicated,
while in stable conditions with exertional symptoms, watchful
waiting and medical therapy is the treatment of choice.167 In
all patients, if there is a deterioration in clinical status, an invasive
strategy is indicated. In the case of recurrent coronary dissec-
tions, pre-term delivery can be considered according to fetal via-
bility. Data on emergency coronary artery bypass graft surgery
during pregnancy are rare, with a potentially high mortality
rate.163,164
Medical therapy. The use of ACE inhibitors, angiotensin receptor
blockers (ARBs), and renin inhibitors is contraindicated during
pregnancy (see Section 11). b-Blockers and low dose acetylsa-
licylic acid are considered to be relatively safe, while this is
unknown for thienopyridines. Clopidogrel should therefore only
be used during pregnancy when strictly needed (e.g. after stent-
ing) and for the shortest duration possible. In the absence of
safety data regarding glycoprotein IIb/IIIa inhibitors, bivalirudin,
prasugrel, and ticagrelor, the use of these dugs is not rec-
ommended during pregnancy.
Delivery. In most cases, vaginal delivery will be appropriate. Delivery
is discussed in Section 2.9.
6.3 Recommendations for the
management of coronary artery disease
7. Cardiomyopathies and heart
failure
The current incidence rate of cardiomyopathies associated with
pregnancy in Europe is not known. The aetiology of cardiomyo-
pathies occurring in association with pregnancy is diverse, with
acquired and inherited [peripartum cardiomyopathy (PPCM),
toxic cardiomyopathy, hypertrophic cardiomyopathy (HCM),
dilated cardiomyopathy (DCM), storage disease, etc.] forms of
cardiomyopathy. Cardiomyopathies are rare diseases but may
cause severe complications in pregnancy.168
7.1 Peripartum cardiomyopathy
PPCM has recently been reviewed.168 The most important
aspects are briefly described here. The incidence varies from
1:300 to 1:4000 pregnancies, emphasizing the involvement of
genetic and/or cultural factors.168,169 Predisposing factors seem
to be multiparity and multiple childbirths, family history, ethni-
city, smoking, diabetes, hypertension, pre-eclampsia,
Table 13 Recommendations for the management of
coronary artery disease
Recommendations Classa Levelb
ECG and troponin levels should be performed 
in the case of chest pain in a pregnant woman.
I C
Coronary angioplasty is the preferred 
reperfusion therapy for STEMI during 
pregnancy.
I C
A conservative management should be 
considered for non ST-elevation ACS without 
risk criteria.
IIa C
An invasive management should be considered 





ACS ¼ acute coronary syndrome; ECG ¼ electrocardiogram; NSTEMI ¼ non
ST-elevation myocardial infarction; STEMI ¼ ST-elevation myocardial infarction.
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malnutrition, advanced age of mothers or teenage pregnancy,
and prolonged use of b-agonists.168,169 The aetiology of PPCM
is uncertain; infections, inflammation, and autoimmune processes
may play a role.170 PPCM is suspected to be the consequence of
an unbalanced oxidative stress leading to proteolytic cleavage of
the lactating hormone prolactin into a potent angiostatic factor
and into pro-apoptotic fragments.171
According to current definitions, PPCM is an idiopathic cardio-
myopathy presenting with heart failure secondary to LV systolic
dysfunction towards the end of pregnancy or in the months follow-
ing delivery. It is a diagnosis of exclusion when no other cause of
heart failure is found. The LV may not be dilated, but the EF is
nearly always reduced below 45%.168
Symptoms and signs are often typical for heart failure but, due to
the special physiological situation of pregnancy and post-partum, a
broad spectrum of symptoms is reported in PPCM patients. PPCM
should be suspected in all women with a delayed return to the pre-
pregnancy state. Frequently the patients present with acute heart
failure. Complex ventricular arrhythmias and sudden cardiac
arrest are also described.
In some cases, not all diagnostic criteria may be strictly fulfilled.
Echocardiography is the preferred method to assess LV function.
Genetically transmitted DCM may manifest in the same time inter-
val and is not distinguishable from PPCM.172,173
Management
Heart failure in PPCM can develop very rapidly, and the guidelines
for the management of acute heart failure apply.174
Interventions
If a patient is dependent on inotropes despite optimal medical
therapy, she should be transferred to a facility where intra-aortic
balloon pump counterpulsation, ventricular assist devices, and
transplant consult teams are available. Use of aortic counterpul-
sation and implantation of an assist device should be discussed
with specialists. It is important to note that the prognosis of
PPCM is different from that of DCM, with a significant pro-
portion improving or normalizing their LV function over the
first 6 months after diagnosis. The relatively high rate (50%)
of spontaneous recovery must be considered when decisions
are made.175
Devices and cardiac transplantation
For women presenting with symptoms and severe LV dysfunc-
tion 6 months following first presentation, despite optimal
medical therapy and QRS duration .120 ms, most clinicians
would advise cardiac resynchronization therapy or implantable
cardioverter-defibrillator (ICD) treatment. Cardiac transplan-
tation should be reserved for patients where mechanical circula-
tory support is not possible or not desirable for individual
reasons or for patients who do not recover after 6–12
months on mechanical circulatory support. Patients with PPCM
have a similar prognosis after transplantation to patients with
DCM.176
Medical therapy
For treatment of chronic heart failure, the pregnancy status of
the patient is important. Most patients with PPCM present
peri- or post-partum. Women who present with PPCM during
pregnancy require joint cardiac and obstetric care. Possible
adverse effects on the fetus must be considered when
prescribing drugs. Urgent delivery, irrespective of gestation,
may need to be considered in women presenting or remaining
in advanced heart failure with haemodynamic instability. As
soon as the baby is delivered, and the patient is haemodynami-
cally stable, standard therapy for heart failure can be applied
(Section 7.4).
Care should be taken with anticoagulation therapy in the
immediate phase after delivery but, once the bleeding is
stopped, it should be considered in patients with very low EF
because peripheral embolism including cerebral embolism and
ventricular thrombi are frequent in PPCM patients.168 This is in
part due to increased procoagulant activity in the peripartum
phase.177
Heart failure should be treated according to guidelines on
acute and chronic heart failure.174 During pregnancy, ACE inhibi-
tors, ARBs, and renin inhibitors are contraindicated because of
fetotoxicity.178,179 When ACE inhibitors are needed during
breastfeeding, benazepril, captopril, or enalapril should be pre-
ferred. Hydralazine and nitrates can be used instead of ACE
inhibitors/ARBs for afterload reduction. Dopamine and levosi-
mendan can be used if inotropic drugs are needed. b-Blocker
treatment is indicated for all patients with heart failure, if toler-
ated.3 b1-Selective drugs (i.e. metoprolol) should be preferred.
Atenolol should not be used.180 Newborns should be supervised
for 24–48 h after delivery to exclude hypoglycaemia, bradycar-
dia, and respiratory depression. Diuretics should only be used
if pulmonary congestion is present since they may decrease
blood flow over the placenta.169 Furosemide and hydrochlor-
othiazide are most frequently used. Aldosterone antagonists
should be avoided.181 Spironolactone can be associated with
antiandrogenic effects in the first trimester. Data for eplerenone
are lacking.
Coagulation activity is increased during pregnancy (see Section
2.4).177 In the context of reduced EF in PPCM, treatment with
LMWH or oral anticoagulation should be considered. Anticoagula-
tion is recommended in patients with intracardiac thrombus
detected by imaging or evidence of systemic embolism,174 as
well as in patients with heart failure and paroxysmal or persistent
AF. LMWH or vitamin K antagonists are recommended according
to the stage of pregnancy to prevent stroke.142,174,182. When
LMWH is used, anti-Xa levels should be monitored.
Delivery
Vaginal delivery is always preferable if the patient is haemodynami-
cally stable and there are no obstetric indications for caesarean
delivery. Close haemodynamic monitoring is required. Epidural
analgesia is preferred. Pre-term delivery has been reported in
17% of patients with no marked negative effects on the child.183
Urgent delivery irrespective of gestation duration should be
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considered in women with advanced heart failure and haemo-
dynamic instability despite treatment. Caesarean section is rec-
ommended with combined spinal and epidural anaesthesia.184 An
experienced interdisciplinary team is required.
Breastfeeding
Some ACE inhibitors (benazepril, captopril, enalapril) have been
sufficiently tested in breastfeeding women and use by the
mother is safe for the babies.185 Children’s weight monitoring
during the first 4 weeks is essential as an indicator of kidney
dysfunction. A recent small prospective randomized pilot
study supports the hypothesis that the addition of bromocrip-
tine to standard heart failure therapy has beneficial effects on
ventricular EF and clinical outcome in women with acute
severe PPCM.186 In addition, due to high metabolic demands
of lactation and breastfeeding, preventing lactation may be
considered.
Prognosis and counselling for repeated pregnancy
Worldwide data about mortality rates vary from 0% to 9% in the
white population of the USA to up to 15% in African Americans as
well as in populations in South Africa and Haiti. Systematic studies
from European countries are not available so far. Deterioration in
LV function is reported in up to 50% of cases despite optimal
medical treatment.187
A subsequent pregnancy carries a recurrence risk for PPCM
of 30–50%.169,175 When the EF has not normalized, a sub-
sequent pregnancy should be discouraged. Even if the EF is
normalized, there is still a need for counselling because of the
risk of recurrence with a new pregnancy.
7.2 Dilated cardiomyopathy
DCM is defined by the presence of typical symptoms of heart
failure, LV dilation, and LV systolic dysfunction of unknown
origin. Differentiation from PPCM is supported by the time of
manifestation. If not known before conception, the condition is
most often unmasked during the first or second trimester when
the haemodynamic load is increasing. A family history of DCM
speaks in favour of the DCM diagnosis and against PPCM. The
few cases of classical DCM in pregnancy describe marked deterio-
ration during pregnancy.188
Secondary cardiomyopathies, such as infiltrative or toxic cardio-
myopathies, or storage diseases and other rare forms, can also
manifest themselves in pregnancy. Hypertensive or ischaemic
heart diseases can also cause similar clinical pictures.
Maternal and offspring risk
Women with DCM should be informed about the risk of deterio-
ration of the condition during gestation and peripartum (see
Section 2). They should be counselled based on individual risk stra-
tification. If pregnancy occurs, LVEF ,40% is a predictor of high
risk, and close monitoring in a tertiary centre should be advised.
If LVEF is ,20%, maternal mortality is very high and termination
of the pregnancy should be considered.
Management
Anticoagulation with LMWH or Vitamin K antagonists according to
stage of pregnancy should be considered for those with atrial
arrhythmias.
DCM is treated in accordance with the current ESC/European
Society of Intensive Care Medicine (ESICM) guidelines for heart
failure,174 with the adaptations during pregnancy described above
for PPCM.
7.3 Hypertrophic cardiomyopathy
HCM is the most common genetic cardiac disease.189 The disease
is frequently diagnosed for the first time in pregnancy by echocar-
diography. The most common substrates for complications are
diastolic dysfunction due to the hypertrophied non-compliant
myocardium, severe LVOTO, and arrhythmias.
The symptoms are typical for heart failure, with pulmonary con-
gestion due to the increased end-diastolic pressure or syncope
during physical activity as a response to outflow tract obstruction.
Echocardiography is the diagnostic tool of choice. Supraventricular
and ventricular arrhythmias are common.
Maternal and offspring risk
Women with HCM usually tolerate pregnancy well. Risk is
increased in women who are symptomatic before pregnancy and
in those with a high outflow tract gradient. Patients with a high
risk clinical profile before pregnancy are at higher risk and need
specialized obstetric care.34,190 Low risk cases may have a spon-
taneous labour and vaginal delivery.
Management
b-Blockers should be considered in those patients with more than
mild LVOTO and/or maximal wall thickness .15 mm to prevent
sudden pulmonary congestion during exertion or emotional
stress.189 b-Blockers can be used for rate control in AF and to sup-
press ventricular arrhythmias. Verapamil can be used as a second
choice when b-blockers are not tolerated (be aware of causing
AV block in the fetus). Cardioversion should be considered for
persistent arrhythmia because AF is poorly tolerated. Therapeutic
anticoagulation with LMWH or vitamin K antagonists according to
stage of pregnancy is recommended for those with paroxysmal or
persistent AF. Patients with a past history or family history of
sudden death need close surveillance with prompt investigation if
symptoms of palpitations or pre-syncope are reported.
Delivery
Low risk cases may have a spontaneous labour and vaginal delivery.
Nevertheless, complications may occur; therefore, a planned deliv-
ery is recommended in all others. The severity of LVOTO will
determine if regional anaesthesia is acceptable. Epidural anaesthesia
causes systemic vasodilation and hypotension, and therefore must
be used with caution in patients with severe LVOTO. I.v. fluids
must be given judiciously and volume overload must be avoided
as it is poorly tolerated in the presence of diastolic dysfunction.
Syntocinon may cause hypotension, arrhythmias, and tachycardia,
and should only be given as a slow infusion.
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7.4 Recommendations for the
management of heart failure
8. Arrhythmias
Both premature extra beats and sustained tachyarrhythmias
become more frequent and may even manifest for the first time
during pregnancy. Symptomatic exacerbation of paroxysmal
supraventricular tachycardia (SVT) occurs during pregnancy in
20–44% of cases.60 Even though most palpitations are benign,
new onset of VT is of concern and the patients should be investi-
gated for the presence of underlying structural heart disease.
The major concern regarding the use of antiarrhythmic drugs
during pregnancy is their potential adverse effects on the fetus.
All antiarrhythmic drugs should be regarded as potentially toxic
to the fetus. While the first trimester is associated with the great-
est teratogenic risk, drug exposure later in pregnancy may confer
adverse effects on fetal growth and development as well as
increase the risk of proarrhythmia. Major controlled studies of anti-
arrhythmic drugs during pregnancy are lacking. Antiarrhythmic
drugs are listed in Section 11.
The risk and benefit of continuing vs. stopping medication must
be given careful consideration because of the potential problem of
recurring tachyarrhythmia during pregnancy. These decisions are
individualized and based on the nature of the arrhythmia and the
underlying heart disease. It is important that symptomatic
tachyarrhythmia is treated by catheter ablation prior to pregnancy
where possible.
8.1 Arrhythmias associated with
structural and congenital heart disease
Supraventricular and ventricular arrhythmias requiring treatment
develop in up to 15% (mean 5%) of patients with congenital
heart diseases during pregnancy.56 Episodes of sustained tachycar-
dia, particularly atrial flutter, are not well tolerated and can cause
fetal hypoperfusion in structural heart disease. Direct current con-
version should be performed to restore sinus rhythm. Digoxin can
be used to control ventricular rate, but has no prophylactic anti-
arrhythmic effect. b-Blocking agents, class I antiarrhythmic drugs,
and sotalol should be used with caution if the LV or RV function
is impaired (see Section 11). Amiodarone should be used only
when other therapy has failed and then at the lowest effective
dose (see Section 11).
8.2 Specific arrhythmias
8.2.1 Supraventricular tachycardia
Atrioventricular nodal re-entry tachycardia and atrioventricular re-entry
tachycardia
AV nodal re-entry tachycardia or AV re-entry tachycardia involving
an accessory pathway can be terminated by vagal manoeuvres or, if
that fails, by i.v. adenosine.191 I.v. adenosine is the first drug of
choice if vagal manoeuvres fail to terminate an episode of parox-
ysmal SVT.191 I.v. metoprolol is recommended if adenosine fails
to terminate a tachycardia. Prophylactic antiarrhythmic drug
therapy should be used only if symptoms are intolerable or if
the tachycardia causes haemodynamic compromise (Table 15).
Then digoxin or a selective b-blocking agent (metoprolol) are
the first-line agents, followed by sotalol, flecainide, or propafe-
none.192 AV nodal blocking agents should not be used in patients
with manifest pre-excitation on resting ECG. Catheter ablation
should be considered only in special cases if necessary during
pregnancy.
Table 14 Recommendations for the management of
cardiomyopathies and heart failure
Recommendations Classa Levelb
Anticoagulation is recommended in patients 
with intracardiac thrombus detected by 
imaging or with evidence of systemic 
embolism.
I A 174
Women with HF during pregnancy should 
be treated according to current guidelines 
for non-pregnant patients, respecting 
contraindications for some drugs in 
pregnancy—see Section 11 Table 21.
I B 168
Women with DCM should be informed about 
the risk of deterioration of the condition 
during gestation and peripartum.
I C
In patients with a past history or family 
history of sudden death close surveillance 
with prompt investigation is recommended if 
symptoms of palpitations or presyncope are 
reported. 
I C
Therapeutic anticoagulation with LMWH 
or vitamin K antagonists according to 
stage of pregnancy is recommended for 
patients with atrial fibrillation.
I C
Delivery should be performed with β-blocker 
protection in women with HCM.
IIa C
β-blockers should be considered in all patients 
with HCM and more than mild LVOTO or  
maximal wall thickness >15mm to prevent  
sudden pulmonary congestion. 
IIa C
In HCM, cardioversion should be considered 
for persistent atrial fibrillation. 
IIa C
Due to high metabolic demands of lactation 
and breastfeeding, preventing lactation may
be considered in PPCM.
IIb C
Subsequent pregnancy is not recommended 





DCM ¼ dilated cardiomyopathy; HCM ¼ hypertrophic cardiomyopathy; HF ¼
heart failure; LMWH ¼ low molecular weight heparin; LVEF ¼ left ventricular
ejection fraction; LVOTO ¼ left ventricular outflow tract obstruction; PPCM ¼
peripartum cardiomyopathy.
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Treatment of cases of atrial tachycardia during pregnancy is gener-
ally more challenging with respect to their drug-resistant nature,
tendency to be persistent, and their association with structural
heart disease. Rate control, using b-blocking agents and/or digitalis,
should be used to avoid tachycardia-induced cardiomyopathy. Pro-
phylactic antiarrhythmic drug therapy includes flecainide, propafe-
none, or sotalol for patients with definite symptoms. Amiodarone
should be used only if the arrhythmia cannot be controlled with
other agents.
Electrical cardioversion is in general not recommended due
to recurrence of tachycardia. Approximately 30% of atrial
tachycardias may be terminated by adenosine. Catheter
ablation should be considered in drug-resistant and poorly toler-
ated cases.
8.2.2 Atrial flutter and atrial fibrillation
Atrial flutter and AF are very rare during pregnancy unless struc-
tural heart disease or hyperthyroidism is present. A rapid ventricu-
lar response to these arrhythmias can lead to serious
haemodynamic consequences for both the mother and the fetus.
Diagnosis and treatment of the underlying condition are therefore
the first priorities. Electrical cardioversion should be performed in
the case of haemodynamic instability.
In haemodynamically stable patients with structurally normal
hearts, pharmacological termination of atrial flutter and AF
should be considered. I.v. ibutilide or flecainide is usually effective,
and may be considered, but the experience during pregnancy is
very limited.193 Since there is even less or no experience of i.v.
propafenone and the new class III antiarrhythmic drug, vernacalant,
i.v. for pharmacological conversion of AF during pregnancy, these
drugs may only be considered if all other attempts at cardioversion
fail. Amiodarone is not recommended, unless other options fail,
due to its fetotoxic effects.
Cardioversion of atrial flutter and AF, whether conducted
electrically or by drugs, does require prior anticoagulation
therapy and/or transoesophageal echocardiographic examination
to exclude left atrial thrombus formation.182 Anticoagulation
(warfarin, substituted with UFH or LMWH in the first and last
trimester) is considered mandatory for at least 3 weeks
before elective cardioversion for AF or atrial flutter of 48 h dur-
ation or longer, or when the duration of AF is unknown,182 and
should be continued for at least 4 weeks after cardioversion
because of the risk of thrombo-embolism related to so-called
‘atrial stunning’.
For patients with AF duration ,48 h and no thrombo-embolic
risk factors, i.v. heparin or weight-adjusted therapeutic dose
LMWH may be considered pericardioversion, without the need
for post-cardioversion oral anticoagulation. Indications for prophy-
lactic antiarrhythmic drugs and anticoagulation relate to the pres-
ence of symptoms and the presence of risk factors for
thrombo-embolism, respectively.182 In patients with risk factors
for stroke or AF recurrence, antithrombotic treatment should
continue lifelong irrespective of apparent maintenance of sinus
rhythm following cardioversion.182
Anticoagulation in atrial fibrillation
The thrombo-embolic risk in AF depends upon the presence of
risk factors. Patients without structural heart disease or risk
factors (‘lone atrial fibrillation’) have the lowest risk of
thrombo-embolic events and do not require anticoagulation or
antiplatelet therapy outside of or during pregnancy; however,
studies during pregnancy are not available. An increase in
thrombo-embolic risk in non-valvular AF is assessed with the
CHADS2 criteria182 and the CHA2DS2VASC score
142 in non-
pregnant patients. In these, a benefit of oral anticoagulation is
documented when the thrombo-embolic risk is ≥4.0 events per
100 patient years (correlates to ≥2 risk points with the
CHADS2 score or 2 risk points with the CHA2DS2VASC score).
Therefore, also in pregnant patients, thromboprophylaxis is rec-
ommended in high risk patients. The choice of the anticoagulant
is made according to the stage of pregnancy. Vitamin K antagonists
are recommended in most cases from the second trimester until 1
month before expected delivery.142 Subcutaneous administration
of weight-adjusted therapeutic doses of LMWH is recommended
during the first trimester and during the last month of pregnancy.
The new oral thrombin antagonists such as dabigatran have shown
fetotoxicity with high doses and should not be used. Either single
or dual antiplatelet therapy (clopidogrel and acetylsalicylic acid)
were not as effective as warfarin in high risk patients with atrial
fibrillation.142,194
Studies in non-pregnant older patients show that LMWH is
effective and can be used if appropriate monitoring is available.
Subcutaneous administration of weight-adjusted therapeutic
doses is recommended during the first trimester and during the
last month of pregnancy.
Rate control
Controlling the ventricular rate with AV nodal blocking drugs
including digoxin, b-blocking agents, and non-dihydropyridine
calcium channel antagonists (verapamil, diltiazem) should be con-
sidered.182 For heart rate control of AF, b-blockers are rec-
ommended as first choice. Digoxin can also be used but is less
effective during strenuous exercise.195 Digoxin blood concen-
trations are unreliable in pregnancy because of interference with
immunoreactive serum components.196 Verapamil should be the
drug of second choice.
Prophylactic antiarrhythmic drugs (sotalol, flecainide, or propa-
fenone) may be considered in the case of severe symptoms
despite rate-controlling drugs.182 Flecainide and propafenone
should be combined with AV nodal blocking agents. Dronedarone,
a new antiarrhythmic drug, should not be used during pregnancy.
8.2.3 Ventricular tachycardia
Life-threatening ventricular arrhythmias during pregnancy are rare.
The presence of inherited arrhythmogenic disorders should always
be considered by family history and appropriate diagnostic tests
during or after pregnancy.61
In healthy patients idiopathic right ventricular outflow tract
tachycardia is the most frequent type, and should be treated
according to established guidelines using either verapamil or a
b-blocking agent as prophylaxis if associated with severe
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symptoms or haemodynamic compromise.61,197 Catheter ablation
of idiopathic RV outflow tract tachycardia may be considered if
associated with haemodynamic compromise and if drug treatment
fails.
VT associated with structural heart disease is associated with an
increased risk of sudden cardiac death for the mother.198 PPCM
should always be ruled out in women presenting with new-onset
ventricular tachycardia during the last 6 weeks of pregnancy or
in the early post-partum period.
For acute treatment of VT with haemodynamic instability,
immediate cardioversion, which seems safe in all phases of
pregnancy, is recommended. Timely restoration of sinus rhythm
is desirable even if VT is well tolerated, and can be achieved
with cardioversion, anti-arrhythmic medication, or, in selected
cases, overdrive pacing. In women with non-long QT-related sus-
tained VT and a stable haemodynamic situation, i.v. sotalol
acutely can be considered to terminate the tachycardia. In patients
with stable monomorphic VT, i.v. procainamide, although not
available in many countries, may be considered. I.v. amiodarone
should be considered for patients with sustained monomorphic
VT that is haemodynamically unstable, refractory to conversion
with countershock, or recurrent despite other agents. I.v. amiodar-
one is not ideal for early conversion of stable monomorphic VT.
Close monitoring of BP is recommended in the presence of LV
dysfunction.
Prophylactic therapy with a cardioselective b-blocking agent,
such as metoprolol, may be effective. Sotalol or class IC anti-
arrhythmic drugs may be considered in the absence of structural
heart disease if b-blocking agents are ineffective. Amiodarone
and/or ICD implantation should be considered to treat
therapy-resistant VT if necessary also during pregnancy for protec-
tion of maternal life.61,199
In women with the congenital long QT syndrome, the risk of
cardiac arrest is greater during the post-partum period compared
with before or during pregnancy.200 b-Blocking agents have a
major benefit post-partum but are also recommended during preg-
nancy in these women.
8.3 Interventional therapy: catheter
ablation
Catheter ablation may be necessary in the case of drug-refractory
and poorly tolerated tachycardias. Due to the high radiation
exposure, ablation should be postponed to the second trimester
if possible, and it should be performed at an experienced ablation
centre with suitable lead shielding and maximal use of echo- and
electro-anatomic mapping systems. Fetal radiation dose and risk
from catheter ablation procedures during pregnancy have been cal-
culated25 (see Section 2.5).
8.4 Implantable
cardioverter-defibrillator
The presence of an ICD does not itself contraindicate future preg-
nancy. Treatment with an ICD should also be considered during
pregnancy to protect the mother’s life.61,199 In general, if pregnancy
is planned, the implantation of an ICD should be considered in
patients with high risk factors for sudden cardiac death.199
8.5 Bradyarrhythmias
Bradyarrhythmias and conduction disturbances are rare during
pregnancy. Asymptomatic bradyarrhythmias may become sympto-
matic due to demands of higher heart rate and CO in patients with
structural heart disease.201 However, bradyarrhythmias usually
have a favourable outcome in the absence of underlying heart
disease.
8.5.1 Sinus node dysfunction
Sinus bradycardia may appear as a reflex cardiac slowing (Valsalva
manoeuvre) during delivery. Rare cases of sinus bradycardia have
been attributed to the supine hypotensive syndrome of preg-
nancy, caused by uterine compression of the inferior vena cava
blood return with paradoxical sinus slowing. In the rare instance
that symptomatic bradycardia occurs, it should be managed by
changing the position of the mother to a left lateral decubitus
position. For persistent symptoms, a temporary pacemaker may
be necessary.
8.5.2 Atrioventricular blocks
First-degree AV block can be observed during pregnancy in the
absence of underlying heart disease. The site of AV delay is
usually located above the bundle of His and does not progress
to complete heart block. Second-degree AV block occurs rarely,
and is usually associated with structural heart disease or drug
therapy. The majority of cases are second-degree type I Wencke-
bach block, unassociated with symptomatic bradycardias. In
patients with congenital heart disease, second-degree block most
commonly occurs in cases of repaired tetralogy of Fallot and less
often after repair of VSDs.
Acquired complete heart block, most often seen in congenital
heart disease after corrective surgery, is rare during pregnancy.
Thirty per cent of congenital AV blocks remain undiscovered
until adulthood, and may present during pregnancy.201 Isolated
congenital complete heart block has a favourable outcome
during pregnancy, especially when the escape rhythm has a
narrow QRS complex. Supportive pacing during pregnancy is
usually not necessary. Vaginal delivery carries no extra risks in a
mother with congenital complete heart block, unless contraindi-
cated for obstetric reasons.
8.5.3 Pacing in pregnancy
Temporary pacing during delivery is recommended in selected
women with complete heart block and symptoms due to the
risk of bradycardia and syncope.
The risks of permanent pacemaker implantation (preferably one
chamber) are generally low. Implantation can be performed safely,
especially if the fetus is beyond 8 weeks gestation. Echo guidance
may be helpful for implantation.202
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8.6 Recommendations for the
management of arrhythmias
9. Hypertensive disorders
Hypertensive disorders in pregnancy remain a major cause of
maternal, fetal, and neonatal morbidity and mortality in developing
and in developed countries. These women are at higher risk for
severe complications such as abruptio placentae, cerebrovascular
accident, organ failure, and disseminated intravascular coagulation.
The fetus is at risk for intrauterine growth retardation, prematurity,
and intrauterine death. Hypertension is the most common medical
problem in pregnancy, complicating up to 15% of pregnancies and
accounting for about a quarter of all antenatal admissions.203
Table 15 Recommendations for the management of arrhythmias
Recommendations Classa Levelb
Management of supraventricular tachycardia (SVT)
For acute conversion of paroxysmal SVT, vagal manoeuvre followed by i.v. adenosine is recommended. I C
Immediate electrical cardioversion is recommended for acute treatment of any tachycardia with haemodynamic instability. I C
For long-term management of SVT oral digoxinc or metoprolol/propranololc,d, is recommended. I C
For acute conversion of paroxysmal SVT, i.v. metoprolol or propranolol should be considered. IIa C
For long-term management of SVT, oral sotalole or flecainidef should be considered if digoxin or a β-blocking agent fails. IIa C
For acute conversion of paroxysmal SVT, i.v. verapamil may be considered. IIb C
For long-term management of SVT, oral propafenonef, or procainamide may be considered as a last option if other suggested agents fail and 
before amiodaronee is used.
IIb C
For long-term management of SVT, oral verapamilc may be considered for rate regulation if the other AV nodal-blocking agents fail. IIb C
Atenolold should not be used for any arrhythmia. III C
Management of ventricular tachycardia (VT)
The implantation of an ICD, if clinically indicated, is recommended prior to pregnancy but is also recommended whenever indicated, 
during pregnancy.
I C
For long-term management of the congenital long QT syndrome, β-blocking agents are recommended during pregnancy and also 
postpartum when they have a major benefit.
I C
For long-term management of idiopathic sustained VT oral metoprololc,d, propranololc,d or verapamilc,f is recommended. I C
Immediate electrical cardioversion of VT is recommended for sustained, unstable, and stable VT. I C
For acute conversion of VT that is sustained, haemodynamically stable, and monomorphic, i.v. sotalole or procainamide should be 
considered.
IIa C
Implantation of permanent pacemakers or ICDs (preferably one chamber) should be considered with echocardiographical guidance, 
especially if the fetus is beyond 8 weeks gestation. 
IIa C
For acute conversion of VT that is sustained, monomorphic, haemodynamically unstable, refractory to electrical cardioversion or not 
responding to other drugs, i.v. amiodaronee should be considered.
IIa C
For long-term management of idiopathic sustained VT oral sotalole, flecainidef, propafenonef should be considered if other drugs fail. IIa C
Catheter ablation may be considered in the case of drug-refractory and poorly tolerated tachycardias. IIb C




cAV nodal blocking agents should not be used in patients with pre-excitation on resting ECG.
db-Blocking agents should be used with caution in the first trimester; see Section 11.
eClass III drugs should not be used in cases with prolonged QTc.
fConsider AV nodal blocking agents in conjunction with flecainide and propafenone for certain atrial tachycardias.
AV ¼ atrioventricular; ECG, electrocardiogram; ICD ¼ implantable cardioverter-defibrillator; i.v. ¼ intravenous; SVT ¼ supraventricular tachycardia; VT ¼ ventricular
tachycardia.
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9.1 Diagnosis and risk assessment
High BP readings should be confirmed on two occasions,204 using
mercury sphygmomanometry (Korotkoff V for reading DBP) in
the sitting position, or an aneroid device. BP measurements in
the left lateral recumbency are a reasonable alternative. Only vali-
dated measuring devices and validated ambulatory BP monitoring
(ABPM) devices should be used (see: www.dableducational.org).
Hypertension in pregnancy, as diagnosed by ABPM, is superior
to the office measurement of BP in predicting outcomes.205,206
Basic laboratory investigations recommended for monitoring
pregnant patients with hypertension include urinalysis, blood
count, haematocrit, liver enzymes, serum creatinine, and serum
uric acid. Proteinuria should be standardized in 24 h urine collec-
tion (if .2 g/day, close monitoring is warranted; if .3 g/day, deliv-
ery should be considered). Ultrasound investigation of the adrenals
and urine metanephrine and normetanephrine assays may be con-
sidered in pregnant women with hypertension to exclude pheo-
chromocytoma which may be asymptomatic and, if not
diagnosed before labour, fatal.207 Doppler ultrasound of uterine
arteries, performed during the second trimester (.16 weeks), is
useful to detect uteroplacental hypoperfusion, which is associated
with a higher risk of pre-eclampsia and intrauterine growth retar-
dation, in both high risk and low risk women.208
9.2 Definition and classification of
hypertension in pregnancy
The definition of hypertension in pregnancy is based on absolute
BP values (SBP ≥140 mmHg or DBP ≥90 mmHg).209,210 and dis-
tinguishes mildly (140–159/90–109 mmHg) or severely (≥160/
110 mmHg) elevated BP, in contrast to the grades used by the
European Society of Hypertension (ESH)/ESC,210 or others.211
Hypertension in pregnancy is not a single entity but comprises:212
† pre-existing hypertension
† gestational hypertension
† pre-existing hypertension plus superimposed gestational hyper-
tension with proteinuria
† antenatally unclassifiable hypertension.
9.2.1 Pre-existing hypertension
Pre-existing hypertension complicates 1–5% of pregnancies and is
defined as BP ≥140/90 mmHg that either precedes pregnancy or
develops before 20 weeks of gestation. Hypertension usually per-
sists .42 days post-partum. It may be associated with proteinuria.
Undiagnosed hypertensive women may appear normotensive in
early pregnancy because of the physiological BP fall commencing in
the first trimester. This may mask the pre-existing hypertension
and, when hypertension is recorded later in pregnancy, it may be
interpreted as gestational.
9.2.2 Gestational hypertension
Gestational hypertension is pregnancy-induced hypertension with
or without proteinuria, and complicates 6–7% of pregnancies. It
is associated with clinically significant proteinuria (≥0.3 g/day in a
24 h urine collection or ≥30 mg/mmol urinary creatinine in a
spot random urine sample) and is then known as pre-eclampsia.
Gestational hypertension develops after 20 weeks gestation and
resolves in most cases within 42 days post-partum. It is character-
ized by poor organ perfusion.
Pre-eclampsia is a pregnancy-specific syndrome that occurs after
mid-gestation, defined by the de novo appearance of hypertension,
accompanied by new-onset of significant proteinuria .0.3 g/24 h.
It is a systemic disorder with both maternal and fetal manifes-
tations. Oedema is no longer considered part of the diagnostic cri-
teria, as it occurs in up to 60% of normal pregnancies. Overall,
pre-eclampsia complicates 5–7% of pregnancies,213 but increases
to 25% in women with pre-existing hypertension. Pre-eclampsia
occurs more frequently during the first pregnancy, in multiple
fetuses, hydatidiform mole, or diabetes. It is associated with placen-
tal insufficiency, often resulting in fetal growth restriction.
Additionally, pre-eclampsia is one of the most common causes
of prematurity, accounting for 25% of all infants with very low
birth weight (,1500 g).214
Symptoms and signs of severe pre-eclampsia include:
† right upper quadrant/epigastric pain due to liver oedema+
hepatic haemorrhage
† headache+ visual disturbance (cerebral oedema)
† occipital lobe blindness
† hyperreflexia+ clonus
† convulsions (cerebral oedema)
† HELLP syndrome: haemolysis, elevated liver enzymes, low plate-
let count.
Management of pre-eclampsia focuses essentially on recognition of
the condition and, ultimately, delivery of the placenta, which is
curative.
As proteinuria may be a late manifestation of pre-eclampsia, it
should be suspected when de novo hypertension is accompanied
by headache, visual disturbances, abdominal pain, or abnormal lab-
oratory tests, specifically low platelet count and abnormal liver
enzymes; it is recommended to treat such patients as having
pre-eclampsia.
9.2.3 Pre-existing hypertension plus superimposed
gestational hypertension with proteinuria
When pre-existing hypertension is associated with further
worsening of BP and protein excretion ≥3 g/day in 24 h urine col-
lection after 20 weeks gestation, it is classified as ‘pre-existing
hypertension plus superimposed gestational hypertension with
proteinuria’.
9.2.4 Antenatally unclassifiable hypertension
When BP is first recorded after 20 weeks gestation and hyperten-
sion (with or without systemic manifestation) is diagnosed, it is
antenatally unclassifiable hypertension. Re-assessment is necessary
at or after 42 days post-partum.
9.3 Management of hypertension
in pregnancy
The majority of women with pre-existing hypertension in preg-
nancy have mild to moderate hypertension (140–160/90–
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109 mmHg), and are at low risk for cardiovascular complications
within the short time frame of pregnancy. Women with essential
hypertension and normal renal function have good maternal and
neonatal outcomes and are candidates for non-drug therapy
because there is no evidence that pharmacological treatment
results in improved neonatal outcome. Some women with
treated pre-existing hypertension are able to stop their medication
in the first half of pregnancy because of the physiological fall in BP
during this period. However, close monitoring and, if necessary,
resumption of treatment is necessary.
The only trial of treatment of hypertension in pregnancy with
adequate infant follow-up (7.5 years) was performed .30 years
ago with a-methyldopa.215,216
9.4 Non-pharmacological management
and prevention of hypertension
in pregnancy
Non-pharmacological management should be considered for preg-
nant women with SBP of 140–150 mmHg or DBP of 90–
99 mmHg, or both. A short-term hospital stay may be required
for confirming the diagnosis of and ruling out severe gestational
hypertension (pre-eclampsia), in which the only effective treat-
ment is delivery. Management depends on BP, gestational age,
and the presence of associated maternal and fetal risk factors,
and includes close supervision, limitation of activities, and some
bed rest in the left lateral position. A normal diet without salt
restriction is advised, particularly close to delivery, as salt restric-
tion may induce low intravascular volume. Calcium supplemen-
tation of at least 1 g daily during pregnancy almost halved the
risk of pre-eclampsia without causing any harm. The effect was
greatest for high risk women.217 However, the evidence for
added calcium in the prevention of hypertensive disorders is con-
flicting. Fish oil supplementation218 as well as vitamin and nutrient
supplements have no role in the prevention of hypertensive dis-
orders. Low dose acetylsalicylic acid (75–100 mg/day) is used pro-
phylactically in women with a history of early-onset (,28 weeks)
pre-eclampsia.219 It should be administered at bedtime, starting
pre-pregnancy or from diagnosis of pregnancy, but before 16
weeks gestation, and should be continued until delivery. Weight
reduction is not recommended during pregnancy in obese
women, because it can lead to reduced neonatal weight and
slower subsequent growth in infants of dieting obese mothers.
However, as maternal obesity can result in negative outcomes
for both women and fetuses, guidelines for healthy ranges of
weight gain in pregnancy have been established. In pregnant
women with normal body mass index (BMI ,25 kg/m2), the rec-
ommended weight gain is 11.2–15.9 kg; for overweight pregnant
women (BMI 25.0–29.9 kg/m2) it is 6.8–11.2 kg; and for obese
pregnant women (BMI ≥30 kg/m2) the recommended weight
gain is ,6.8 kg.220
9.5 Pharmacological management of
hypertension in pregnancy
Drug treatment of severe hypertension in pregnancy is required
and beneficial, yet treatment of less severe hypertension is
controversial. Although it might be beneficial for the mother
with hypertension to reduce her BP, a lower BP may impair uter-
oplacental perfusion and thereby jeopardize fetal development.
Women with pre-existing hypertension may continue their
current medication except for ACE inhibitors, ARBs, and direct
renin inhibitors, which are strictly contraindicated in pregnancy
because of severe fetotoxicity, particularly in the second and
third trimesters (Table 21). If taken inadvertently during the first
trimester, switching to another medication and close monitoring
including fetal ultrasound are advisable and usually are sufficient.
a-Methyldopa is the drug of choice for long-term treatment of
hypertension during pregnancy.216 The a-/b-blocker labetalol has
efficacy comparable with methyldopa. If there is severe hyperten-
sion it can be given i.v. Metoprolol is also recommended.221
Calcium channel blockers such as nifedipine (oral) or isradipine
(i.v.) are drugs of second choice for hypertension treatment.222
These drugs can be administered in hypertensive emergencies or
in hypertension caused by pre-eclampsia. Potential synergism
with magnesium sulfate may induce maternal hypotension and
fetal hypoxia. Urapidil can also be selected for hypertensive emer-
gencies. Magnesium sulfate i.v. is the drug of choice for treatment
of seizures and prevention of eclampsia. Diuretics should be
avoided for treatment of hypertension because they may decrease
blood flow in the placenta. They are not recommended in
pre-eclampsia.
9.5.1 Treatment of mild to moderate hypertension
The benefits and risks of antihypertensive therapy for mild to mod-
erate hypertension (defined as SBP of 140–169 mmHg and DBP of
90–109 mmHg) are still controversially discussed. Current ESH/
ESC guidelines210 recommend as the thresholds for antihyperten-
sive treatment an SBP of 140 mmHg or a DBP of 90 mmHg in
women with:
† gestational hypertension (with or without proteinuria)
† pre-existing hypertension with the superimposition of gesta-
tional hypertension
† hypertension with subclinical organ damage or symptoms at any
time during pregnancy.
In any other circumstances, the ESH/ESC thresholds are an SBP of
150 mmHg and a DBP of 95 mmHg. This Task Force recommends
following these guidelines.
9.5.2 Treatment of severe hypertension
There is also no agreement on the definition of severe hypertension,
with values ranging between 160 and 180 mmHg/. 110 mmHg. This
Task Force recommends considering an SBP ≥170 mmHg or DBP
≥110 mmHg in a pregnant woman as an emergency, and hospitaliz-
ation is indicated. The selection of the antihypertensive drug and its
route of administration depend on the expected time of delivery.
Pharmacological treatment with i.v. labetalol, or oral methyldopa, or
nifedipine should be initiated. I.v. hydralazine is no longer the drug of
choice as its use is associated with more perinatal adverse effects
than other drugs. The drug of choice in hypertensive crises is
sodium nitroprusside given as an i.v. infusion at 0.25–5.0 mg/kg/min.
Prolonged treatment with sodium nitroprusside is associated with
an increased risk of fetal cyanide poisoning as nitroprusside is
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metabolized into thiocyanate and excreted into urine.223 The drug of
choice in pre-eclampsia associated with pulmonary oedema is nitro-
glycerine (glyceryl trinitrate), given as an i.v. infusion of 5 mg/min,
and gradually increased every 3–5 min to a maximum dose of
100 mg/min.
Delivery
Induction of delivery is indicated in gestational hypertension with
proteinuria with adverse conditions such as visual disturbances,
coagulation abnormalities, or fetal distress.
Breastfeeding
Breastfeeding does not increase BP in the nursing mother. Bromo-
criptine, which is used to suppress lactation, may induce hyperten-
sion.224 All antihypertensive agents taken by the nursing mother
are excreted into breast milk. Most of the antihypertensive drugs
are present at very low concentrations, except for propranolol
and nifedipine, whose concentrations in breast milk are similar to
those in maternal plasma.
9.6 Prognosis after pregnancy
9.6.1 Blood pressure post-partum
Post-partum hypertension is common. BP usually rises after deliv-
ery over the first 5 days. Hypertensive women during pregnancy
may be normotensive after birth but then become hypertensive
again in the first postnatal week. Methyldopa should be avoided
post-partum because of the risk of post-natal depression.
9.6.2 Risk of recurrence of hypertensive disorders
in a subsequent pregnancy
Women experiencing hypertension in their first pregnancy are at
increased risk in a subsequent pregnancy.225 The earlier the
onset of hypertension in the first pregnancy, the greater the risk
of recurrence.226
9.6.3 Long-term cardiovascular consequences
in pregnancy-induced hypertension
Women who develop gestational hypertension or pre-eclampsia
are at increased risk of hypertension and stroke in later adult
life.227 as well as of ischaemic heart disease.228,229 The relative
risk of developing ischaemic heart disease after pre-eclampsia is
more than twice as high compared with women with normal preg-
nancies, and the risk of developing hypertension is almost four-
fold.229 Women with early-onset pre-eclampsia (delivery before
32 weeks of gestation), with stillbirth, or fetal growth retardation
are considered to be at highest risk.229 Risk factors before preg-
nancy for the development of hypertensive disorders are high
maternal age, elevated BP, dyslipidaemia, obesity, positive family
history, antiphospholipid syndrome, and glucose intolerance.
Hypertensive disorders in pregnancy have been recognized as an
important risk factor for CVD in women.230 Therefore, lifestyle
modifications, regular BP control, and control of metabolic
factors are recommended after delivery, to avoid complications
in subsequent pregnancies and to reduce maternal cardiovascular
risk in the future.
9.7 Recommendations for the
management of hypertension
10. Venous thrombo-embolism
during pregnancy and the
puerperium
10.1 Epidemiology and maternal risk
Pregnancy and the puerperium are associated with an increased
incidence of venous thrombo-embolism (VTE), occurring in 0.05–
0.20% of all pregnancies.231–235 VTE encompassing pulmonary embo-
lism and deep vein thrombosis (DVT) represents a significant cause
of pregnancy-related morbidity and mortality. Pulmonary embolism is
the most common cause of direct maternal death in the UK, with an
incidence of 1.56 deaths per 100 000 pregnancies, and the second
most common cause of maternal death overall.9 The case fatality rate
Table 16 Recommendations for the management of
hypertension
Recommendations Classa Level b
Non-pharmacological management for pregnant 
women with SBP of 140-150 mmHg or DBP of 
90-99 mmHg is recommended.
I C
In women with gestational hypertension or 
pre-existing hypertension superimposed by 
gestational hypertension or with hypertension 
and subclinical organ damage or symptoms at 
any time during pregnancy, initiation of drug 
treatment is recommended at a BP of 140/90 
mmHg. In any other circumstances, initiation of 
drug treatment is recommended if SBP ≥150 
mmHg or DBP ≥95 mmHg.
I C
SBP ≥170 mmHg or DBP ≥110 mmHg in 
a pregnant woman is an emergency, and 
hospitalization is recommended.
I C
Induction of delivery is recommended in 
gestational hypertension with proteinuria with 
adverse conditions such as visual disturbances, 
coagulation abnormalities, or fetal distress.
I C
In pre-eclampsia associated with pulmonary 
oedema, nitroglycerine given as an intravenous 
infusion, is recommended.
I C
In severe hypertension, drug treatment with 
intravenous labetalol or oral methyldopa or 
nifedipine is recommended.
I C
Women with pre-existing hypertension 
should be considered to continue their 
current medication except for ACE inhibitors, 





ACE ¼ angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BP ¼
blood pressure; DBP ¼ diastolic blood pressure; SBP ¼ systolic blood pressure.
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is 3.5%.236 The risk of VTE is highest in the immediate post-partum
period,232 particularly after caesarean section,235 and returns to the
non-pregnant level after the sixth week post-partum.231,232
10.2 Risk factors for pregnancy-related
venous thrombo-embolism and risk
stratification
The presence of risk factors (see Tables 17 and 18) contributes
to the increased risk of VTE during pregnancy and the puerper-
ium. Seventy nine percent of women dying from an antenatal pul-
monary embolism in the UK had identifiable risk factors.9,236 The
most significant risk factors for VTE in pregnancy are a prior
history of unprovoked DVT or pulmonary embolism237 and
thrombophilias (Table 18). From 15% to 25% of VTEs are recur-
rent events. Half of the women who develop a thrombotic event
during pregnancy have either a thrombophilic disorder or a pre-
vious idiopathic VTE.
Therefore, identification of risk factors in the individual
patient is important for risk assessment and choice of preventive
strategies. All women should undergo a documented assessment
of risk factors for VTE before pregnancy or in early pregnancy.
Table 17 provides a suggested checklist for documentation of
this risk assessment.238 On the basis of the type and the total
number of risk factors present in the individual patient, three
risk groups can be identified (high, intermediate, and low risk
groups) and preventive measures applied accordingly (see
Table 19).238 Previous recurrent VTEs and previous VTE—
unprovoked or oestrogen related—are considered high risk
factors. The exact influence of the other single risk factors or
the summation of several risk factors on total VTE risk is not
known.
10.3 Prevention of venous
thrombo-embolism
Prospective, non-randomized studies showed that in women with
risk factors not receiving anticoagulation the recurrence rate of
Table 17 Check list for risk factors for venous
thrombo-embolism modified according to the Royal
College of Obstetricians and Gynaecologists238
Pre-existing risk factors
Previous recurrent VTEa
Previous VTE—unprovoked or oestrogen relatedb
Previous VTE—provoked
Family history of  VTE
Known thrombophiliac
Medical co-morbidities, e.g.heart or lung diseases, SLE, cancer, inflammatory 
conditions, nephritic syndrome, sickle cell disease, i.v. drug use
Age >35 years







Multiple pregnancy or assisted reproductive therapy
Emergency caesarean section
Elective caesarean section
Mid-cavity or rotational forceps
Prolonged labour (>24 hours)




Surgical procedure in pregnancy or <6 weeks post-partum
aPatients with previous recurrent VTEs (.1), or those with ba previous unprovoked
or oestrogen-related VTE belong to the high risk group (see Table 19).
cSee Table 18.
dObesity based on booking weight.
Example: in a pregnant woman with a family history of VTE, age .35 years, and
obesity (BMI. 30 kg/m2, the total number of risk factors is 3. This patient belongs to
the intermediate risk group and requires VTE prophylaxis accordingly (see Table 19).
BMI¼ body mass index; i.v.¼ intravenous; SLE ¼ systemic lupus erythematosus;
VTE¼ venous trombo-embolism.
Table 18 Prevalence of congenital thrombophilia and
the associated risk of venous thrombo-embolism during








Factor V Leiden mutation
Heterozygous 2.0–7.0 8.32 (5.44,12,70)
Homozygous 0.2–0.5 34.40 (9.86, 120.05)
Prothrombin G20210A mutation
Heterozygous 2.0 6.80 (2.46, 18.77)
Homozygous Rare 26.36 (1.24, 559.29)
Antithrombin deficiency 
(<80% activity)
<0.1–0.6 4.76 (2.15, 10.57)
Protein C deficiency
(<75% activity)
0.2–0.3 4.76 (2.15, 10.57)
Protein S deficiency
(<65% activity)
<0.1–0.1 2.19 (1.48, 6.00)
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VTE ranged from 2.4% to 12.2%, in comparison with 0–2.4% in
patients who did receive anticoagulation.241
LMWH has become the drug of choice for the prophylaxis and
treatment of VTE in pregnant patients.242 It causes less bone loss
than UFH, and the osteoporotic fracture rate is lower (0.04% of
pregnant women treated with LMWH).242
The dose of LMWH for thromboprophylaxis is based on the
booking weight. There are no data to guide appropriate doses of
LMWH for pregnant women who are obese or puerperal. It is
agreed that women of higher weights should receive higher doses,
but there are no studies available on the optimal dose and weight
ranges. Patients at high risk for VTE (see Table 19) should receive
the usual prophylactic dose of 0.5 IU /kg body weight of enoxaparin
or 50 IU/kg body weight dalteparin twice daily.




The clinical symptoms and signs of pulmonary embolism during
pregnancy are the same as in the non-pregnant state (dyspnoea,
chest pain, tachycardia, haemoptysis, and collapse). Subjective clini-
cal assessment of pulmonary embolism is, however, more difficult,
because dyspnoea and tachycardia are not uncommon in normal
pregnancy.
Diagnosis
Clinical prediction rules for assigning pre-test probabilities of
VTE have been validated in the non-pregnant patient, as well
as the use of D-dimer testing, compression ultrasonography,
and computed tomographic pulmonary angiography (CTPA)
and ventilation perfusion lung scanning for pulmonary embolism
diagnosis.243 This is not the case in pregnant women.244 Also
the diagnostic algorithms which are well established for the diag-
nosis of VTE in the general population have not been validated
in the pregnant patient. This complicates recommendations and
calls urgently for multicentre, prospective studies. A high index
of suspicion is important for the timely diagnosis of VTE. All
pregnant women with signs and symptoms suggestive of VTE,
particularly dyspnoea of acute onset or worsening, should
have objective testing performed expeditiously as in non-
pregnant patients.
D-Dimer and compression ultrasonography. D-Dimer levels increase
physiologically with each trimester. In one study the mean pre-
conception D-dimer concentration was 0.43 (SD 0.49) mg/L,
and rose in the first, second, and third trimester to 0.58 mg/L
(SD 0.36), 0.83 (SD 0.46) mg/L, and 1.16 (SD 0.57) mg/L,
respectively, indicating a 39% relative increase in D-dimer con-
centration for each trimester compared with the previous
one.245 Thus a positive D-dimer test based on the conventional
cut-off level is not necessarily indicative of VTE and new cut-off
levels are needed. Further objective testing is required.
Table 19 Risk groups according to risk factors, definition and preventive measures modified according to the Royal
College of Obstetricians and Gynaecologists238




(i) Previous recurrent VTE (>1) or
(ii) VTE unprovoked / oestrogen–related 
or
(iii) Single previous VTE +  thrombophilia or family history
High risk patients should receive antenatal prophylaxis with 
LMWH as well as post-partum for the duration of 6 weeks.   
Graduated compression stockings are also recommended 




(i) 3 or more risk factors other than listed above as high risk
(ii) 2 or more risk factors other than listed as high risk if 
 patient is admitted to hospital
In intermediate risk patients antenatal prophylaxis with LMWH 
should be considered.                   
Prophylaxis is recommended postpartum for at least 7 days or 
longer, if >3 risk factors persist. 
Graduated compression stockings should be considered during 




<3 risk factors. 
In low risk patients early mobilization and avoidance of 
dehydration is recommended.
Several risk scores for identification of patients at different risk levels have been developed,240 yet all risk scores, including the above, still need validation in prospective studies.
LMWH ¼ low molecular weight heparin; VTE, venous thrombo-embolism.
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However, a negative D-dimer test is helpful to exclude VTE,
although there are a few cases of VTE reported with normal
D-dimer concentrations.246 The recommendation to measure
D-dimer levels in all pregnant women with the clinical suspicion
of VTE is still controversial.243 Yet it is the consensus of
this Task Force that the D-dimer concentration should be
measured in patients with suspected pulmonary embolism,
followed by bilateral compression ultrasonography. If this is
normal in the presence of negative D-dimer levels, then pulmon-
ary embolism is unlikely and anticoagulation with LMWH is not
warranted.
In patients with suspected pulmonary embolism, positive
D-dimer levels and positive compression ultrasonography, antic-
oagulation treatment is indicated. If D-dimer levels are elevated
and compression ultrasonography is negative in patients with
suspected pulmonary embolism, further testing is required.
MRI does not involve radiation exposure, is probably not
harmful to the fetus, and has a high sensitivity and specificity
for the diagnosis of iliac vein thrombosis. CT pulmonary angio-
graphy should be performed, when the diagnosis cannot be con-
firmed or excluded with the above-discussed tools. In these
patients it is preferred over ventilation–perfusion lung scanning
for the diagnosis of pulmonary embolism243; both are associated
with fetal radiation exposure, with ventilation–perfusion lung
scanning delivering a higher fetal dose of radiation than CT pul-
monary angiography (see Table 3 in Secion 2). However, radi-
ation doses are below the limit that is regarded as dangerous
for the fetus.243,247
Treatment
LMWH. LMWH has also become the drug of choice for the treat-
ment of VTE in pregnancy and puerperium. The efficacy and
safety of several LMWH preparations was shown in a review of
2777 pregnant women, treated for DVT or pulmonary embolism.
The risk of recurrent VTE with treatment doses of LMWH was
1.15%. The observed rate of major bleeding was 1.98%.
Heparin-induced thrombocytopenia is markedly lower with
LMWH than with UFH as is heparin-induced osteoporosis
(0.04%).242 In clinically suspected DVT or pulmonary embolism,
treatment with LMWH should be given until the diagnosis is
excluded by objective testing.
Dosage. The recommended therapeutic dose is calculated on body
weight (e.g. enoxaparin 1 mg/kg body weight twice daily, Dalte-
parin 100 IU/kg body weight twice daily) aiming for 4–6 h peak
anti-Xa values of 0.6–1.2 IU/mL.248
Monitoring. The necessity to monitor anti-Xa values regularly in
patients with VTE is still controversial. Whereas it is
considered necessary in patients with mechanical valves in
whom LMWH is used (see Section 5), this is not so clear in
patients with VTE. Given the need for dose increase as preg-
nancy progresses to maintain a certain therapeutic anti-Xa
level,153,154 it seems reasonable to determine anti-Xa levels
also during pregnancy in patients with VTE. This appears par-
ticularly justified in view of the fact that pulmonary embolism
occurred in women receiving preventive doses of LMWH.236
This topic also requires further studies. A simple guide is
dose adjustment according to increasing weight during
pregnancy.
UFH. UFH also does not cross the placenta, but is associated with
more thrombocytopenia, osteoporosis, and more frequent dosing
when given subcutaneously compared with LMWH. It is favoured
in patients with renal failure and when urgent reversal of anticoa-
gulation by protamine is needed, as well as in the acute treatment
of massive pulmonary emboli.
Dosage. In patients with acute pulmonary embolism with haemo-
dynamic compromise, i.v. administration of UFH is recommended
(loading dose of 80 U/kg, followed by a continuous i.v infusion of
18 U/kg/h).
Monitoring. The aPTT has to be determined 4–6 h after the loading
dose, 6 h after any dose change, and then at least daily when in the
therapeutic range. The therapeutic target aPTT ratio is usually 1.5–
2.5 times the average laboratory control value. The dose is then
titrated to achieve a therapeutic aPTT, defined as the aPTT that
corresponds to an anti-Xa level of 0.3–0.7 IU/mL. When haemo-
dynamics are improved and the patient is stabilized, UFH can be
switched to LMWH in therapeutic doses and maintained during
pregnancy. LMWH should be switched to i.v. UFH at least 36 h
before the induction of labour or caesarean delivery. UFH
should be discontinued 4–6 h before anticipated delivery, and
restarted 6 h after delivery if there are no bleeding complications.
Neither UFH nor LWMH is found in breast milk in any significant
amount and they do not represent a contraindication to
breastfeeding.
Thrombolysis. Thrombolytics are considered to be relatively con-
traindicated during pregnancy and peripartum and should only
be used in high risk patients with severe hypotension or
shock.243 The risk of haemorrhage, mostly from the genital
tract, is 8%.249 In 200 reported patients, mostly streptoki-
nase was used and, more recently, recombinant tissue plasmino-
gen activator. Both thrombolytics do not cross the placenta in
significant amounts. Fetal loss of 6% and 6% pre-term delivery
were reported.250 When thrombolysis has been given, the
loading dose of UFH should be omitted and an infusion
started at a rate of 18 U/kg/h. After stabilization of the
patient, UFH can be switched to LMWH for the residual dur-
ation of pregnancy.
Fondaparinux. There are very few studies on fondaparinux in preg-
nancy; one has shown minor transplacental passage of fondapari-
nux.251 Because of the scarce data, the drug should not be used
in pregnancy (see Section 11).
Rivaroxaban. Rivaroxaban crosses the placental barrier and has
therefore not been evaluated, and is not recommended in preg-
nant patients.
Vena cava filters. Indications for vena cava filters are the same as in
non-pregnant patients. However, the risk associated with the pro-
cedure may be increased.243,250
Post-partum management
In patients with recent pulmonary embolism, pre-partum heparin
treatment should be restarted 6 h after a vaginal birth and 12 h
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after a caesarean delivery, if no significant bleeding has occurred,
with subsequent overlap with vitamin K antagonists for at least 5
days. Vitamin K antagonists may be started on the second day
after delivery and continued for at least 3 months or for 6
months if pulmonary embolism occurred late in pregnancy. The
INR should be between 2 and 3 and needs regular monitoring,
ideally once every 1–2 weeks. Vitamin K antagonists do not
enter the breast milk in active forms and are safe for nursing
mothers.
10.4.2 Acute deep vein thrombosis
Clinical presentation
Leg swelling is a frequent finding in pregnancy, giving rise to the
suspicion of DVT. Since DVT is left sided in .85% of cases, due
to compression of the left iliac vein by the right iliac artery and
the gravid uterus, specifically swelling of the left leg is suspicious.
Isolated iliac vein thrombosis may manifest with isolated pain in
the buttock, groin, flank, or abdomen. A clinical decision rule, con-
sidering three variables: left leg presentation, .2 cm calf circum-
ference difference, and first trimester, allowed a negative
predictive value of 100% (95% CI 95.8–100%) if none of the
three variables was present and ultrasound of the legs was nega-
tive.86 This clinical decision rule needs validation in prospective
studies.
Diagnosis
D-Dimer. See diagnosis of pulmonary embolism.
Compression ultrasound leg vein imaging. Compression ultrasound is
the diagnostic imaging procedure of choice for suspected DVT in
pregnancy with a high sensitivity and specificity for proximal
DVT, yet less for distal DVT and DVT in the vasculature of the
pelvis. Serial compression ultrasound evaluations at days 0, 3,
and 7 in pregnancy gives a high negative predictive value of
99.5% (95% CI 97–99% %).240
All women with suspected DVT in pregnancy should be
assessed for pre-test probability, have D-dimer testing, and then
undergo compression ultrasonography.
If a proximal DVT is detected, treatment should be contin-
ued. In women with a high pre-test probability, a positive
D-dimer and a normal initial compression ultrasound magnetic
resonance venography may be considered to exclude isolated
pelvic DVT. Women with low pre-test probability and normal
D-dimer should undergo serial compression ultrasonography
on day 3 and after 1 week without anticoagulation. When com-
pression ultrasonography remains negative, DVT can be
excluded.
Treatment
In acute DVT, treatment with therapeutic doses of LMWH should
be applied, weight adjusted, twice daily (see treatment of pulmon-
ary embolism).
10.5 Recommendations for the
prevention and management of venous
thrombo-embolism in pregnancy and
puerperium
11. Drugs during pregnancy and
breastfeeding
11.1 General principles
This section summarizes all pertinent drugs and their potential use
during pregnancy and breastfeeding. There are no uniform rec-
ommendations for the treatment of pregnant women yet. This
also concerns the timing of treatment initiation and selection of
Table 20 Recommendations for the prevention and
management of venous thrombo-embolism in
pregnancy and puerperium
Recommendations Classa Levelb
In all women who are pregnant or consider 
pregnancy, assessment of risk factors for VTE 
is recommended.
I C
Mothers should be informed about the signs 
and symptoms of VTE in pregnancy and the 
necessity to contact the physicians if they 
occur.
I C
High risk patientsc should receive antenatal 
prophylaxis with LMWH as well as 
post-partum for the duration of 6 weeks.
I C
In intermediate risk patientsd post-partum 
prophylaxis with LMWH should be given for 
at least 7 days or longer, if >3 risk factors 
persist.
I C
In low risk patientse early mobilization and 
avoidance of dehydration is recommended.
I C
Graduated compression stockings are 
recommended antepartum and post-partum in 
all women at high risk.
I C
D-Dimer measurement and compression 
ultrasonography is recommended in patients 
with suspected VTE during pregnancy.
I C
For treatment of acute VTE during pregnancy, 
UFH is recommended in high-risk and LMWH 
in non-high risk patients.
I C
Graduated compression stockings should be 
considered in women with intermediate risk 
during pregnancy and post-partum.
IIa C
In intermediate risk patients, antenatal 
prophylaxis with LMWH should be considered.
IIa C





LMWH ¼ low molecular weight heparin; UFH, unfractionated heparin; VTE ¼
venous thrombo-embolism.
For definitions of high riskc, intermediate riskd, and low riske, see Table 19.
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medications. As drug treatment in pregnancy concerns the mother
and the fetus, optimum treatment of both must be targeted.
Whether drug treatment is necessary is dependent on the
urgency of the indication.
In case of emergency, drugs that are not recommended by the
pharmaceutical industry during pregnancy and breastfeeding
should not be withheld from the mother. The potential risk of a
drug and the possible benefit of the therapy must be weighed
against each other.
Different sources of evidence can be used for risk classification
of drugs applied during pregnancy.
11.1.1 US Food and Drug Administration classification
This classification has been published by the US Department of
Health and Human Services. (Source: Drug Information for the
Health Care Professional; USDPI Vol 1, Micromedex 23rd edn.,
01.01.2003). Adapted and modified from Bonow et al.46
The classification consists of category A (safest) to X (known
danger—do not use!). The following categories are used for
drugs during pregnancy and breastfeeding.
Category B: either animal reproduction studies have not demon-
strated a fetal risk but there are no controlled studies in preg-
nant women, or animal reproduction studies have shown an
adverse effect that was not confirmed in controlled studies in
women.
Category C: either studies in animals have revealed adverse effects
on the fetus and there are no controlled studies in women, or
studies in women and animals are not available. Drugs should be
given only if potential benefits justify the potential risk to the
fetus.
Category D: there is evidence of human fetal risk, but the benefits
from use in pregnant woman may be acceptable despite the risk
(e.g. treatment of life-threatening conditions).
Category X: studies in animals or human beings have demonstrated
fetal abnormalities, or there is evidence of fetal risk based on
human experience, or both, and the risk of the use of the
drug in pregnant women clearly outweighs any possible
benefit. The drug is contraindicated in women who are or
may become pregnant.
11.1.2 Internet databases
The authors of the database www.embryotox.de of the
Pharmakovigilanz- und Beratungszentrum fu¨r Embryonaltoxikolo-
gie of the Berliner Betrieb fu¨r Zentrale Gesundheitliche Aufgabe
base their recommendations on a combination of scientific
sources, expert opinions, mainly based on observational data,
and personal experiences of women during pregnancy and the
time of breastfeeding.
The English database www.safefetus.com is arranged quite simi-
larly to the German database.
11.1.3 Pharmaceutical industry
The manufacturers’ instructions are mainly based on the fact that
drugs are not tested sufficiently during pregnancy and breastfeed-
ing. For this and for legal reasons, drugs are frequently considered
prohibited during pregnancy and breastfeeding.
11.2 Recommendations for drug use
Table 21 Recommendations for drug use
Drugs
Classification (Vaughan 





Transfer to breast 
milk (fetal dose)
Adverse effects
Abciximab Monoclonal antibody with 
antithrombotic effects
C Unknown Unknown Inadequate human studies; should be given 
only if the potential benefit outweighs the 
potential risk to the fetus.
Acenocoumarola Vitamin K antagonist D Yes Yes (no adverse effects 
reported)
Embryopathy (mainly first trimester), 
bleeding (see further discussion in Section
5 for use during pregnancy).
Acetylsalicylic acid 
(low dose)
Antiplatelet drug B Yes Well-tolerated No teratogenic effects known
(large datasets).
Adenosineb Antiarrhythmic C No No No fetal adverse effects reported (limited 
human data).
Aliskiren Renin inhibitor D Unknown Unknown Unknown (limited experience).
Amiodarone Antiarrhythmic
(Class III)
D Yes Yes Thyroid insufficiency (9%), hyperthyroidism, 







Antibiotics B Yes Yes No fetal adverse effects reported.
Continued
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Enalaprild ACE inhibitor D Yes Yese (maximum 1.6%) Renal or tubular dysplasia, oligohydramnion, 
growth retardation, ossification disorders 
of skull, lung hypoplasia, contractures, large 
joints, anaemia, intrauterine fetal death.
Eplerenone Aldosterone antagonist - Unknown Unknown Unknown (limited experience).
Fenofibrate Lipid-lowering drug C Yes Yes No adequate human data.
Flecainide Antiarrhythmic  (class IC) C Yes Yese Unknown (limited experience).
Fondaparinux Anticoagulant - Yes (maximum 10%) No New drug, (limited experience).
Furosemide Diuretic C Yes Well tolerated; milk 
production can be 
reduced
Oligohydramnion.
Gemfibrozil Lipid-lowering drug C Yes Unknown No adequate human data.
Glyceryl trinitrate Nitrate B Unknown Unknown Bradycardia, tocolytic.
Heparin (low 
molecular weight)
Anticoagulant B No No Long-term application: seldom 
osteoporosis and markedly less 
thrombocytopenia than UF heparin.
Imipenem, rifampicin,
teicoplanin, vancomycin





Antibiotics D Unknown Unknown Risk to the fetus exists
(reserved for vital indications).
Atenololc β-blocker (class II) D Yes Yes Hypospadias (first trimester); birth defects, 
low birth weight, bradycardia and 
hypoglycaemia in fetus (second and 
third trimester). 
Benazeprild ACE inhibitor D Yes Yese (maximum 1.6%) Renal or tubular dysplasia, oligohydramnion, 
growth retardation, ossification disorders 
of skull, lung hypoplasia, contractures, large 
joints, anaemia, intrauterine fetal death.
Bisoprolol β-blocker (class II) C Yes Yes Bradycardia and hypoglycaemia in fetus.
Candesartan Angiotensin II receptor blocker D Unknown Unknown; not 
recommended
Renal or tubular dysplasia, oligohydramnion, 
growth retardation, ossification disorders 
of skull, lung hypoplasia, contractures, large 
joints, anaemia, intrauterine fetal death.
Captoprild ACE inhibitor D Yes Yese (maximum 1.6%) Renal or tubular dysplasia, oligohydramnion, 
growth retardation, ossification disorders 
of skull, lung hypoplasia, contractures, large 
joints, anaemia, intrauterine fetal death.
Clopidogrel Antiplatelet drug C Unknown Unknown No information during pregnancy available.
Colestipol,
cholestyramine
Lipid-lowering drugs C Unknown Yes- lowering fat-
soluble vitamins
May impair absorption of fat-soluble 
vitamins, e.g. vitamin K –> cerebral bleeding 
(neonatal).
Danaparoid Anticoagulant B No No No side effects (limited human data).
Digoxinf Cardiac glycoside C Yes Yese Serum levels unreliable, safe.
Diltiazem Calcium channel blocker 
(class IV)
C No Yese Possible teratogenic effects.
Disopyramide Antiarrhythmic (class IA) C Yes Yese Uterus contraction.
Drugs
Classification (Vaughan 
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Transfer to breast 
milk (fetal dose)
Adverse effects
Quinidine Antiarrhythmic (class IA) C Yes Yese Thrombopenia, premature birth, VIII th 
nerve toxicity.
Ramiprild ACE inhibitor D Yes Yes (maximum 1.6%) Renal or tubular dysplasia, oligohydramnion, 
growth retardation, ossification disorders 
of skull, lung hypoplasia, contractures, large 
joints, anaemia, intrauterine fetal death.
Sotalol Antiarrhythmic (class III) B Yes Yese Bradycardia and hypoglycaemia in fetus 
(limited experience).
Spironolactone Aldosterone antagonist D Yes Yese (maximum1.2%); 
milk production can be 
reduced
Antiandrogenic effects, oral clefts (first
trimester).
Statinsg Lipid-lowering drugs X Yes Unknown Congenital anomalies.
Ticlopidine Antiplatelet C Unknown Unknown Unknown (limited experience).
Heparin 
(unfractionated)
Anticoagulant B No No Long-term application: osteoporosis and 
thrombocytopenia.
Hydralazine Vasodilator C Yes Yese (maximum 1%) Maternal side effect: lupus-like symptoms;
fetal tachyarrhythmias (maternal use).
Hydrochlorothiazide Diuretic B Yes Yes; milk production 
can be reduced
Oligohydramnion.
Irbesartand Angiotensin II receptor blocker D Unknown Unknown Renal or tubular dysplasia, oligohydramnion, 
growth retardation, ossification disorders 
of skull, lung hypoplasia, contractures, large 
joints, anaemia, intrauterine fetal death.
Isosorbide dinitrate Nitrate B Unknown Unknown Bradycardia.
Isradipine Calcium channel blocker C Yes Unknown Potential synergism with magnesium sulfate 
may induce hypotension.
Labetalol α-/ β-blocker C Yes Yese Intrauterine growth retardation 
(second and third trimester), neonatal 
bradycardia and hypotension (used near term).
Lidocaine Antiarrhythmic  (class IB) C Yes Yese Fetal bradycardia, acidosis, central nervous 
system toxicity.
Methyldopa Central α-agonist B Yes Yese Mild neonatal hypotension.
Metoprolol β-blocker (class II) C Yes Yese Bradycardia and hypoglycaemia in fetus.
Mexiletine Antiarrhythmic  (class IB) C Yes Yese Fetal bradycardia.
Nifedipine Calcium channel blocker C Yes Yese (maximum 1.8%) Tocolytic; s.l. application and potential 
synergism with magnesium sulfate may 
induce hypotension (mother) and fetal 
hypoxia.
Phenprocoumona Vitamin K antagonist D Yes Yes (maximum 10%), well 
tolerated as inactive 
metabolite
Coumarin-embryopathy, bleeding (see 
further discussion in Section 5 for use 
during pregnancy).
Procainamide Antiarrhythmic (class IA) C Yes Yes Unknown (limited experience).
Propafenone Antiarrhythmic (class IC) C Yes Unknown Unknown (limited experience).
Propranolol β-blocker (class II) C Yes Yese Bradycardia and hypoglycaemia in fetus.
Continued
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It has been a great privilege for the Chair of this Task Force to have
been able to work with the finest and best reputed experts and
scientists in the field at the European level and to give these Guide-
lines to the community of cardiologists, cardiovascular surgeons,
gynaecologists, and all specialists involved in the care of pregnant
women. On this occasion I would like to thank all members of
the Task Force who so generously shared their knowledge, as
well as the referees for their tremendous input. I would also like
to thank the ESC for making these Guidelines possible. Finally I
would like to express my greatest appreciation of the Guidelines
team at the heart house, especially Veronica Dean and Nathalie
Cameron for their extremely helpful support.
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Table 21 Continued
Valsartand Angiotensin II receptor blocker D Unknown Unknown Renal or tubular dysplasia, oligohydramnion, 
growth retardation, ossification disorders 
of skull, lung hypoplasia, contractures, large 
joints, anaemia, intrauterine fetal death.
Verapamil oral Calcium channel blocker 
(class IV)
C Yes Yese Well tolerated
(limited experience during pregnancy).
Verapamil i.v. Calcium channel blocker 
(class IV)
C Yes Yese Intravenously use is may be associated 




- Unknown Unknown No experience of use in pregnancy.
Warfarina Vitamin K antagonist D Yes Yes (maximum 10%), well 
tolerated as inactive 
metabolite
Coumarin-embryopathy, bleeding (see 









Transfer to breast 
milk (fetal dose)
Adverse effects
aThe Guideline Committee added acenocoumarol and phenprocoumon in analogy to warfarin to this list. The necessity for risk assessment also applies to these two OAC.
Previously the risk category X was attributed to warfarin.46 In the opinion of the Task Force available evidence suggests that risk category D is more appropriate for warfarin and
other vitamin K antagonists (see references and discussion in Section 5.5).
bAdenosine: most of the experiences with this drug are in the second and third trimesters. Its short half-life may prevent it from reaching the fetus
cAtenolol is classified D by FDA,252 nevertheless some authors classify as C.253
dThe available data on first-trimester use do not strongly support teratogenic potential.178,179 Because ACE inhibitors, angiotensin II receptor blockers, aldosterone antagonists,
and renin inhibitors should be avoided during pregnancy and breastfeeding the risk category is D. Positive outcomes with ACE inhibitors have been described and pregnancy does
not have to be terminated if the patient was exposed to these medications, but should be followed-up closely.
eBreastfeeding is possible if the mother is treated with the drug.254
fDigoxin: the experience with digoxin is extensive, and it is considered to be the safest antiarrhythmic drug during pregnancy. A prophylactic antiarrhythmic efficacy has never been
demonstrated.
gStatins: should not be prescribed in pregnancy and during breastfeeding since their harmlessness is not proven and disadvantages to the mother are not to be expected by a
temporary interruption of the therapy for the time period of pregnancy.
ACE ¼ angiotensin-converting enzyme; UF ¼ unfractionated.
The CME text ‘ESC Guidelines on the management of cardiovascular diseases during pregnancy’ is accredited by the European Board for Accreditation in Cardiology (EBAC). EBAC
works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of
Medical Specialists (UEMS). In compliance with EBAC/EACCME guidelines, all authors participating in this programme have disclosed potential conflicts of interest that might
cause a bias in the article. The Organizing Committee is responsible for ensuring that all potential conflicts of interest relevant to the programme are declared to the participants
prior to the CME activities.
CME questions for this article are available at: European Heart Journal http://cme.oxfordjournals. org/cgi/hierarchy/oupcme_node;ehj and European Society of Cardiology http://
www.escardio.org/guidelines.
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